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Session 1: Sex hormones and aromatases in chronic 
inflammation and cancer
1 
The steroid cascade in NEI – an overview
Rainer H Straub
Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, 
University Hospital Regensburg, Germany
Cholesterol is the starting point of synthesis of steroid hormones and vitamin D. 
Thus, its uptake, storage, transport, and conversion into respective downstream 
hormones is of outstanding importance. Cholesterol is taken up into the cell by 
the cholesterol uptake receptor SR-BI. In adrenal glands, it is stored as choles-
terol ester in vesicles that gives the organ its characteristic yellow color. Cho-
lesterol ester is degraded by lipases on demand. Cholesterol ester is transported 
into mitochondria where it is converted into pregnenolone, the starting point of 
steroidogenesis. Pregnenolone is converted into a multitude of downstream hor-
mones with the major pathways leading to mineralocorticoids, glucocorticoids, 
and adrenal androgens. In chronic inflammatory diseases, these pathways are al-
tered so that the major pathway to glucocorticoids is up-regulated at the expense 
of adrenal androgens. Nevertheless, the amount of secreted glucocorticoids is in-
adequate in relation to systemic inflammation leading to relative insufficiency. In 
the animal model of experimental arthritis, we recently demonstrated mitochon-
drial defects in the chronic phase of the disease which most probably contributes 
to inadequate low levels of glucocorticoids in relation to inflammation. This pres-
entation highlights defects and alterations in steroidogenesis. These alterations 
belong to an adaptive program positively selected for short-lived inflammatory 
episodes but not for chronic life-long inflammation. 
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Gender-dependent regulation and roles of the p200-family 
cytosolic DNA sensors: implications for sex bias in autoimmunity 
Divaker Choubey & Ravichandran Panchanathan
Department of Environmental Health, University of Cincinnati & Cincinnati 
Veterans Affairs (VA) Medical Center, USA 
The development of certain autoimmune diseases in patients and mouse models 
exhibit a gender bias. Although studies implicated factors such as the X-chro-
mosomal gene dosage effect and sex hormones (such as estrogen) in gender bias 
in the development of autoimmune diseases, the molecular mechanisms remain 
unclear. Development of autoimmune diseases and their progression involve im-
mune dysregulation at the interface between the innate and adaptive immune 
systems. Accumulating evidence indicates that a defective clearance of cellu-
lar debris, which can activate innate immune responses, contributes to a loss 
of self-tolerance, autoantibody production (against nuclear antigens and DNA), 
and the formation of immune complexes (ICs). Several clinical manifestations of 
autoimmune diseases are believed to be the result of autoantibody and immune 
complex deposition in tissues and organs; thus, leading to secondary inflamma-
tory responses and organ damage. Evidence indicates that activation of toll-like 
receptors (TLR)-dependent and independent innate immune responses, which re-
sult in increased production of type I interferon-α/β (IFN-α/β) and an increased 
expression of the IFN-inducible genes (“IFN-signature”) contribute to the de-
velopment of disease phenotype in certain autoimmune diseases (which include 
systemic lupus erythematosus or SLE). We have identified a mutually-positive 
regulatory feedback loop between IFN-α/β and the estrogen receptor-α (ERα) in 
immune cells. Further, our studies revealed that the expression of certain IFN-in-
ducible p200-family proteins (such as human IFI16 and murine p202 and Aim2) 
that act as innate immune sensors for cytosolic DNA is differentially regulated 
by the sex hormones. Upon sensing the cytosolic DNA, the p200-family proteins 
either assemble an inflammasome or induce expression of type I IFNs through 
an activation of the STING/TBK1/IRF3 axis. Activation of the DNA-responsive 
Aim2 inflammasome promotes secretion of pro-inflammatory cytokines (such as 
IL-1β and IL-18). Further, increased levels of estrogen and IFN-inducible p202 
protein in immune cells potentiate the production of type I IFNs and induce ex-
pression of the B-cell activating factor (BAFF) and Unc93b1 (a transporter of 
certain TLRs). In conclusion, our studies identified the molecular mechanisms 
through which the p200-family innate immune sensors for the cytosolic DNA 
contribute to sex bias in the development of certain autoimmune diseases.
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Glucocorticoids, sex and life and death
Danielle Duma and John A. Cidlowski
Molecular Endocrinology Group, Laboratory of Signal Transduction, NIH/NI-
EHS, MD F3-07, P. O. Box 12233 Research Triangle Park, North Carolina, 27709
Glucocorticoids are necessary for life after birth and regulate numerous biologi-
cal processes in man, including glucose homeostasis, protein catabolism, skeletal 
growth, respiratory function, inflammation, development, behavior and apoptosis. 
They are also one of the most prescribed classes of drugs in the world particularly 
for diseases involving inflammation. Interestingly, males and females exhibit dis-
tinct differences in the prevalence of many major diseases, including autoimmune 
disease, hepatocellular carcinoma, diabetes, and osteoporosis, which all have im-
portant inflammatory components in their etiology. These gender-specific diseases 
are largely considered to reflect the actions of sex hormones on the susceptibility 
to inflammatory stimuli. However, inflammation is recognized to reflect a balance 
between pro- and anti-inflammatory signals and glucocorticoids are the primary 
physiological anti-inflammatory hormone in mammals. Synthetic derivatives of 
these hormones are extensively prescribed as anti-inflammatory agents, irrespec-
tive of patient gender. We explored the possibility the sexually dimorphic actions 
of glucocorticoid regulation of gene expression may contribute to the dimorphic 
basis of inflammatory disease by evaluating the rat liver, a classic glucocorticoid-
responsive organ. Surprisingly, glucocorticoid administration expanded the pro-
file of hepatic sexually dimorphic genes. Pathway analysis identified sex-specific 
glucocorticoid-regulated gene expression in several canonical pathways involved 
in susceptibility to progression of diseases with gender differences in prevalence. 
These gender specific actions of glucocorticoids in liver were substantiated in vivo 
using a sepsis model of systemic inflammation.  
4. 
Estrogens metabolism and autoimmunity
*Maurizio Cutolo, *Alberto Sulli, **Rainer H Straub
*Research Laboratory and Academic Unit of Clinical Rheumatology, Department 
of Internal Medicine, University of Genova, Italy
** Laboratory of Experimental Rheumatology & Neuroendocrine Immunology, 
Department of Internal Medicine I, University Hospital of Regensburg, Regens-
burg, Germany
All players of the immune response including B cells, T cells, antigen-presenting 
cells and macrophages have different capacities to take up, to metabolize estro-
gens (called intracrinology) and to be modulated (1). Estrogen metabolism de-
pends on transport into cells, desulfation of sulfated estrogens, sulfatation of non-
sulfated estrogens, androgen aromatization, estrogen conversion to downstream 
hydroxylated or methylated estrogens. Furthermore, up- or downregulation of 
estrogen receptors alpha and beta (in cells or on the cell surface), of co-activators, 
and of co-repressors might well depend on involved cells and microenvironmen-
tal conditions such as accompanying hypoxia, local growth factors and proin-
flammatory cytokines. In addition, it has been demonstrated, but in one animal 
model, that 17β–estradiol accelerates immune-complex glomerulonephritis but 
may ameliorate focal sialadenitis, renal vasculitis, and periarticular inflammation 
(2). These data might suggest that different pathologies might even be present in 
the same human individual so that estrogens and/or their peripheral metabolites 
may have beneficial effects on one aspect of the disease but a different influ-
ence on other mechanisms. The different response most probably on involved 
cell types, concentrations and notably on peripheral estrogen metabolism rate 
and even by use of animal models to test hypothesis (3). Very recent studies also 
showed that the small change of estrogen or progesterone levels during therapy 
with oral contraceptives or hormone replacement therapy has variable power to 
increase the risk or severity of B cell-related autoimmune diseases (i.e. systemic 
lupus erythematosus or anticardiolipin syndrome), with more evident effects on 
overt disease. Moreover, estrogens can even stimulate several immune mecha-
nisms at postmenopausal levels due to their bimodal role described (3). Interest-
ingly, there are important similarities between chronic inflammatory diseases and 
inflammatory reactions in certain types of cancer such as breast cancer or prostate 
cancer. In inflammatory tissue of patients with RA, estrogen precursors are par-
ticularly converted into 16-hydroxylated estrogens, which are pro-proliferative 
and covalently bound to the estrogen receptor type alpha, whereas, generation of 
anti-proliferative 2-hydroxylated estrogens is blocked (4). Conversion can hap-
pen in synovial macrophages and fibroblasts. Similarly, macrophages in breast 
cancer tissue can convert precursor hormones to 16-hydroxylated estrogens with 
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a similar increase of estrogenic effects (5). Similar to precursor 17β-estradiol, 
the converted 16-hydroxylated estrogens can stimulate important growth factors 
such as TGF-β, basic fibroblast growth factor, keratinocyte growth factor, and 
angiogenesis all involved in both chronic inflammation (immune response) and 
cancer. As matter of fact, this is in agreement with the growth-supporting role of 
17β-estradiol during pregnancy. In conclusion, in both chronic immune/inflam-
matory disease and cancer, in which overshooting growth responses play a deci-
sive pathogenic role, the 17β-estradiol-stimulated increase of these growth factors 
is most probably crucial.
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Aromatase and endometriosis: estrogens play a role
Ferrero S, Scala C, Tafi E, Leone Roberti Maggiore U, 
Department of Obstetrics and Gynecology, University of Genova, Italy
Endometriosis is an estrogen dependent inflammatory disease defined by the 
growth of endometrial stroma and glands outside of the uterus. In endometriosis, 
estrogens promote the growth and invasion of endometriotic tissue and prosta-
glandins play a crucial role in the mediation of pain, inflammation, and infertil-
ity. The proliferation and inflammation processes in endometriotic lesions are 
supported by stradiol (E2), the biologically active form of estrogen. It has been 
observed a significant correlation between local estrogen content of endometri-
otic lesions and the expression levels of the steroidogenic enzyme aromatase 
cytochrome P450. Since the late 1990s, several studies using either PCR or im-
munohistochemistry demonstrated the expression of aromatase P450 in both 
eutopic and ectopic endometrium from patients with endometriosis, but not in 
eutopic endometrium from disease-free women and in endometriosis-free perito-
neal tissue. The primary substrate for aromatase activity in endometriotic tissue 
is androstenedion (adrenal and ovarian) that is converted in estrone, which is 
further converted to the more active E2. Aromatase is regulated at the levels of 
transcriptional expression, protein expression, and enzyme activity in endometri-
osis. It is involved in a positive feedback loop that favors expression of key ster-
oidogenic genes. Estrogen stimulates expression of the COX-2 enzyme, resulting 
in elevated levels of prostaglandin E2 (PGE2), which is a potent stimulator of 
aromatase activity in endometriosis. This leads to continuous local production of 
E2 and PGE2 in endometriotic tissue. Over the last 10 years, aromatase inhibitors 
have been proposed for the treatment of endometriosis both in post-menopausal 
women and in subjects of reproductive age. 
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Aromatase and regulation of estrogens: androgens ratio in synovial 
tissue inflammation: a common pathway in both sexes
*Silvia Capellino, **Rainer H. Straub, ***Maurizio Cutolo
*The Johns Hopkins University, School of Medicine, Dept. of Pediatrics, Balti-
more, MD (USA)
**University Hospital Regensburg, Dept. of Internal Medicine I, Regensburg 
(Germany)
***University Hospital San Martino, Dept. of Internal Medicine. Genova (Italy)
Sex hormones play an active role in inflammatory response, with androgens be-
ing anti-inflammatory whereas estrogens are mostly proinflammatory, even if 
they can also act anti-inflammatory dependent on different criteria (1). Clinical 
evidences point out the influence of sex hormones on chronic inflammatory dis-
eases: anti-inflammatory adrenal hormones are low in patients with autoimmune 
diseases compared to controls, and incidence of autoimmune diseases is much 
higher in women compared to men. 
During chronic synovial inflammation, sex hormone metabolism is altered in 
inflamed joints, with low level of androgens and high levels of estrone in the 
synovial fluid of rheumatoid arthritis (RA) patients compared to controls (2). Of 
interest, no differences were observed between male and female patients, thus 
suggesting that local hormone metabolism during inflammation is not dependent 
on gender. Aromatase is the key enzyme for the conversion of androgens into 
estrogens, and it is expressed by differentiated synovial macrophages (3). Proin-
flammatory cytokines such as TNF, IL-1β and IL-6 have been found to stimulate 
aromatase activity in peripheral macrophages, therefore the inflammatory milieu 
during arthritis can stimulate androgen to estrogen conversion and sustain the in-
flammatory process in the synovium. Moreover, gonadal hormones such as dehy-
droepiandrosterone (DHEA), testosterone precursor, and testosterone inhibit aro-
matase activity: if the concentration of androgens is low, aromatase is expressed 
while if their concentration is high, aromatase is repressed (4). Considering that 
local androgen levels are very low in synovial fluid of RA patients compared 
to controls, this unbalanced hormonal concentration can also contribute to high 
aromatase activity in synovial tissue during arthritis. 
Due to the key role of aromatase activity and sex hormone imbalance in the 
synovial tissue during arthritis, a clinical relevance for aromatase inhibitor (AI) 
in arthritis can be suggested. 
However, clinical evidences show an increased occurrence of joint pain in pa-
tients undergoing AI therapy because of estrogen receptor positive breast can-
cer (5). Even if this evidence could seem to contradict aromatase effect on joint 
inflammation, it is important to point out that systemic aromatase blockade can 
influence mechanisms independent of sex hormone levels in the joint, such as 
melatonin pathway, thereby causing joint pain (6).
Another very promising hormone involved in aromatase activity during arthritis 
is vitamin D (Vit D). This steroid hormone was demonstrated to downregulate 
aromatase expression in human breast cancer cells and also in human RA mac-
rophages (7). Moreover, Vit D decreases pro-inflammatory cytokine in human 
activated macrophages, thus suggesting also a direct anti-inflammatory role on 
cytokine production.
Taken together, these evidences suggest a key role of aromatase and sex hormone 
balance in the synovial tissue during chronic inflammation, and point out the im-
portance of vitamin D as possible new tool for modulating aromatase pathway in 
arthritis.
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To compare the efficacy of norethisterone acetate (NETA; group N) 
or letrozole combined with NETA (group L) in treating endometriotic 
ovarian cysts
Umberto Leone Roberti Maggiore
Department of Obstetrics and Gynaecology, San Martino Hospital and National 
Institute for Cancer Research, University of Genova
Objective. To compare the efficacy of norethisterone acetate (NETA; group N) or 
letrozole combined with NETA (group L) in treating endometriotic ovarian cysts. 
Study design. This patient-preference study included 20 patients in group N and 
group L, respectively. The primary aim of the study was to compare the volume 
of the endometriomas during and after treatment. The secondary outcome was 
the evaluation of the changes in pain symptoms during and after treatment. 
Results. After 6-month of treatment, the volume of the endometriomas signifi-
cantly decreased compared with baseline in both study groups; it was smaller in 
group L than in group N (p=0.026). The rate of satisfied patients at 6-month of 
treatment was similar between the study groups (p=0.451). No significant dif-
ference was reported between the two study groups in the amelioration of pain 
symptoms and in the incidence of adverse events. 
Conclusions. Letrozole combined with NETA is more efficacious than NETA 
alone in reducing the volume of endometriotic cysts but in none of the 40 patients 
included in the study the endometriomas disappeared. However the efficacy of 
aromatase inhibitors should be balanced with the need to administer long-term 
treatment and the incidence of adverse events.
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Pregnancy in women with monogenic and non-hereditary autoin-
flammatory syndromes: results from a retrospective multi-centric 
study 
Sfriso P, Marconato M, Caso F, *Cantarini L, *Brizi MG, **Lo Monaco A, 
***Agostini C, Punzi L, Doria A 
Rheumatology Unit, University of Padova
*University of Siena 
**University of Ferrara, Italy
***Hematology and Clinical Immunology Unit, University of Padova
Italy Autoinflammatory diseases (AIDs) are a group of inherited and acquired 
multifactorial syndromes sharing dysregulation of the innate immunity which 
includes familial Mediterranean fever (FMF); tumor necrosis factor receptor-
associated periodic syndrome (TRAPS); Cryopyrin-associated periodic syn-
dromes (CAPS), Familial Cold Autoinflammatory Syndrome (FCAS), Muckle 
Well Syndrome (MWS), Blau’s syndrome (BS); Schnitzler syndrome (SS); Adult 
Onset Still disease (AOSD); Mevalonate Kinase Deficiency (MKD). Despite the 
childbearing age of many patients, few data about the reciprocal relationship 
between AIDs and pregnancy are available to date, due to the low incidence of 
AIDs and the low female-to-male ratio. All patients affected with AIDs who ex-
perienced at least one pregnancy and seen in three Italian referral centers (Rheu-
matology Unit, Department of Medicine, University of Padova; Rheumatology 
Unit, Policlinico Le Scotte, University of Siena; Rheumatology Unit, University 
of Ferrara) were included in the study. Data regarding fetal and maternal out-
comes as well as disease activity during pregnancy were retrospective collected. 
Pregnancies were also sub-divided into two groups according to the time of the 
disease onset: group 1 after the disease onset and group 2 before the disease 
onset. 17 women with AIDs reported 30 pregnancies: 2 in patients with MKD, 
9 with TRAPS, 8 with CAPS, 4 with FCAS and 4 with MWS, 3 with BS, 5 with 
AOSD and 3 with SS. There were 16 pregnancies in group 1 and 14 in group 2. 
Mean maternal age at conception was 27±6 years in group 1 and 30±4 years in 
group 2. Median disease duration at delivery was 13±7 years in group 1 and 15±3 
years in group 2. We recorded the following pregnancy complications (group 1 
vs group 2): gestational hypertension 37,5% vs 14.3%; preeclampsia 18% vs 0; 
abortions 12,5% vs 30%; preterm delivery 12,5% vs 0. No cases of disease wors-
ening were observed during pregnancy in the group 1. By contrast, we recorder 
2 cases (12,5%) of complete remission and 2 cases (12,5%) of partial remission. 
Conclusions. Patients with pregnancy after the disease onset experienced a fre-
quency of gestational hypertension and pre-eclampsia higher than women who 
developed the disease after pregnancy. The disease course remained unaffected 
during pregnancy and postpartum.
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Oestrogens accelerate lupus-like glomerulonephritis in NZB/WF1 
mice
*Bassi N, **Luisetto R, *Gatto M, *Nalotto L, *Bettio S, *Ghirardello A, *Doria 
A. 
*Dep. of Medicine DIMED, University of Padova, Italy 
**Division of Experimental Surgery, University of Padova, Italy
Background. Systemic lupus erythematosus (SLE) is a systemic disease involving 
many organ systems and glomerulonephritis (GLN) is one of the most frequent 
manifestations. Serum levels of oestrogens, androgens, prolactin and other adrenal 
hormones are different in SLE patients compared with healthy subjects and, con-
versely, changes in SLE activity have been observed in physiological conditions, 
such as pregnancy, characterized by fluctuations in hormone serum levels. 
Aim. The aim of the study was to evaluate the effect of oestrogens in the progres-
sion of lupus GLN. 
Materials and methods. Female NZB/WF1 mice, a murine model which spon-
taneously develops a lupus-like GLN at about 5 months of age, were subdivided 
into 2 groups, 8 each: pellets containing 17-β-estradiol, and releasing it at a daily 
dose of 18μg for 90 days, were subcutaneously implanted in the ear by micro-
scissors in the mice of group 1 at week 19, whereas 200μl of PBS were injected 
in the same site and at the same week in group 2, as controls. All mice were bred 
until natural death occurred. Urine samples were weekly collected; blood sam-
ples were collected before the implantation of pellets or PBS injection and every 
4 weeks, thereafter. Proteinuria levels were evaluated by multistix reagent strips 
(Siemens), whereas circulating levels of anti-dsDNA, anti-C1q antibodies, and 
BLyS will be evaluated by standardized home-made ELISA tests. 
Results. Proteinuria-free survival rate (<300mg/dl) was significantly lower in 
group 1 than in control group (p=0.046). At the 30th week 62.5% of group 1 com-
pared with 25% of group 2 developed proteinuria levels ≥300mg/dl (p=0.046). 
At 33rd week 100% mice of group 1 compared with 50% group 2 mice devel-
oped proteinuria levels ≥300mg/dl (p=0.046). Mean proteinuria free survival 
rate (weeks±SD) was significantly lower in group 1 mice than in control group 
(30.0±2.0 vs. 32.4±2.3, p=0.046). Mice survival rate was significantly lower in 
group 1 than in control group (p=0.032). At 30th week of age 50% of group 1 
compared with 12.5% of group 2 were dead (p=0.032), and when the last mouse 
of group 1 (week 34) dead only 75% of group 2 were dead (p=0.032). Mean 
survival (weeks±SD) was significantly lower in group 1 mice than in group 2 
(30.9±2.5 vs. 33.6±2.1, p=0.034). Data on anti-dsDNA and anti-C1q antibody 
levels as well as BLyS serum levels will be presented at the congress. 
Conclusions. Oestrogens seem to accelerate lupus-like GLN in NZB/WF1 mice. 
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Reduced risk for rheumatoid arthritis in women mediated by a 
CYB5A gene polymorphism which increases androgen synthesis
Martin Schmidt1*, Rainer H. Straub2*, Jozef Rovenský3, Stanislava Blažičková3, 
Gabriele Eiselt1, Klaus Stark4,5
1 Dept. Biochemistry II, Jena University Hospital, Germany
2 Dept. Internal Medicine I, University Hospital Regensburg, Germany
3 National Institute of Rheumatic Diseases, Piešt’any, Slovakia
4 Dept. Internal Medicine II, University Hospital Regensburg, Germany
5 Dept. Genetic Epidemiology, University Regensburg, Germany
*, contributed equally
Rheumatoid arthritis (RA) exhibits a clear sex bias with roughly three times more 
affected women than men. The underlying mechanisms remain elusive despite 
intense research efforts. RA is characterized by decreased androgen levels, which 
was the first hormonal abnormality described. Previous studies showed that ster-
oidogenesis is shifted towards endogenous glucocorticoids at the expense of 
anti-inflammatory androgens. The key step governing androgen synthesis is the 
17,20-lyase activity of a CYP17A1-encoded dual function enzyme, whereas its 
17α-hydroxylase is required for androgen and glucocorticoid synthesis alike. 
Only 17,20-lyase activity depends on the presence of a critical cofactor, cy-
tochrome b5 A, encoded by the CYB5A gene. Therefore, we included the CYB5A 
gene in a screening for RA-associated single nucleotide polymorphisms (SNP) in 
genes for steroidogenic enzymes.
The data sets of two genome-wide association studies (GWAS) on RA were 
screened for SNPs in or near the CYPB5A gene. Candidate SNPs in CYPB5A 
were studied in an independent case-control study population of Slovak origin 
(n=521 cases, n=321 controls). Functional analyses were done in synovial fibro-
blasts lines from knee samples of RA patients by quantitative RT-PCR, steroid 
conversion was measured using radiolabeled substrates, and cytochrome b5–ex-
pression was detected by immunohistochemistry.
We identified the RA-associated SNPs rs1790834 in the NARAC/EIRA 
(p=0.0073, OR=0.83) and rs1790858 in the WTCCC (p=0.0095, OR=0.44) co-
hort, respectively. The intronic SNP rs1790834 in the CYB5A gene was confirmed 
in our case-control study. The minor allele reduced RA risk selectively in women 
(p=0.0041, OR=0.63, 95%CI [0.46-0.86]). The protective effect was confined to 
rheumatoid factor-positive (OR=0.53, 95%CI [0.37-0.75]) and anti-cyclic citrul-
linated peptide-positive (OR=0.58, 95%CI [0.41-0.83]) cases, respectively. The 
protective allele doubles CYB5A mRNA-expression, leading to two- to threefold 
activation of steroid 17,20-lyase activity and resulting in accumulation of andro-
gens in fibroblast cultures. Furthermore, increased mRNA-expression was ac-
companied by a higher density of cytochrome b5-positive cells in synovial tissue.
In conclusion, CYB5A is the first RA susceptibility gene shown to be involved in 
androgen synthesis. Our functional analysis of SNP rs1790834 indicates that it 
contributes to the sex bias observed in RA.
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Association between low sex hormone levels and antibody (Ab) 
presence in women with premature ovarian insufficiency (POI) and 
autoimmune diseases (AID) 
Barac B., Vujovic S., Barac M., Ivanisevic M., Ostojic P., Jovic T., Zivojinovic 
S., Stojic B., Damjanov N. 
Institute of Rheumatology, Belgrade, Serbia, Institute of Endocrinology, Belgrade, 
Serbia 
Significant difference in gender specific prevalence of AID after the age of 35 
could be related to sex hormone effect on immune system. Many studies con-
firmed coexistence of AID and POI. Etiology of POI is considered to be hromo-
zomic dearrangement in 2.5%, immunologic diseases in 45% and idiopathic in 
52% cases. AIM: to define the association of low sex hormon levels and antibod-
ies in POI with coexistence AID. 
Methods. 180 women with idiopathic POI (loss of menstrual cycle before age 
of 40, FSH>40IU, E2<50 pmol/l). Women with iatrogenic POI were excluded. 
Patients were divided in two groups: POI Ab(+), 82 women, with presence of at 
least one antibody (antimicrosomal, antithyreoglobulin, antiparietal, anti DNA, 
antinuclear, antimitochondrial, antiphospholipid, antineutrophil, anticardiolipin 
or antiovarian), and POI Ab(-), 98 women without any of these Ab. The groups 
were equal and comparable in age, BMI, time of menarche, last menstruation 
and the length of anovulatory period. The blood was taken for FSH, LH, E2, T, 
DHEAS, SHBG, TSH, T4, PTH and ACTH. 
Results. Existence of AID in POI At (+), vs. POI At(-), group was 46% vs. 6%, 
respectively p<0.05. AID in POI At (+) group: Hashimoto thyreoiditis 38%, SLE 
5%, RA 4%, Sy Sjögren 4%, M.Adissoni 2.5%, Antiphospholipid sy. 1%. AID in 
POI At (-) group: Gluten enteropathy 3%, Hashimoto thyreoididtis 2%, M. Adis-
soni and Collitis ulcerosa 1%. Differences in E2 (estradiol) level in POI Ab(-), 
vs. POI Ab(+), group were 35,3±85.3/ 19,2±34,7 pmol/l, (p=0.22). Differences in 
Testosteron level in POI Ab(-) vs. POI Ab(+) group were 2.34±11.21/0.63±0.94 
nmol/l, (p<0.05). Differences in TSH level in POI Ab (+) vs. POI Ab(-) group, 
were 2.3±3.9/0.6±0.9 IU/l, (p<0.001). There were no significant differences in 
level of FSH, LH, PTH, T4, PRL, SHBG and DHEAS between the two groups. 
Conclusion. AID were found in significantly higher percent of POI Ab(+) patient. 
Lover level of E2, and statistical significant lower level of testosterone found in 
POI Ab(+) group, confirmed the coexistence of lower sex steroid hormone levels 
and AID in POI Ab(+) group. Looking for tissue specific Ab should be a relevant 
diagnostic tool in women in POI. It could distinguish a group of women with po-
tential benefit of immunomodulating therapy in goal to preserve ovarian failure. 
Correction of sex steroid hormone levels, as therapy for POI, modulate autoim-
mune response and could potentially affect the appearance of other AID.
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Androgen in postmenopausal systemic sclerosis patients 
*Perkovic D, *Martinovic Kaliterna D, **Lalovac M, *Krstulovic Marasovic D
*Department of Clinical Immunology and Rheumatology, University Hospital 
Split, Croatia
 **Department of Gastroenterology, General Hospital Dubrovnik, Croatia
Introduction. Systemic sclerosis (SSc) is a chronic connective tissue disease 
characterized by immunological abnormalities, vascular lesions and fibrosis of 
the skin and internal organs.  SSc is occurring more frequently in women sug-
gesting that sex hormones may play an important role in disease pathogenesis. It 
is well-known that prolactin, sex hormones and adrenal androgens have multiple 
immunomodulatory functions. A few studies showed low dehydroepiandrosteron 
sulfate (DHEAS) and testosterone levels in SSc patients and correlation with 
disease severity. 
The aim of this study was to investigate the serum levels of estradiol, testoster-
one, DHEAs and androstendione in postmenopausal SSc patients and to examine 
the possible correlation with autoantibodies in SSc. 
Methods. Twenty-seven post-menopausal SSc patients who fulfiled the prelimi-
nary American College of Rheumatology (ACR) criteria for the classification of 
SSc and twenty-seven healhty women were enroled in the study.  They matched 
for age and post-menopausal duration and none of them had received any hor-
mone replacement therapy. Serum levels of estradiol, testosterone, androstendi-
one and DHEAs were measured in both groups. Serum levels of anticentromeric 
antibodies (ACA) were measured only in SSc patients. 
Results. Serum levels of  testosterone (0,80±0,62 nmol/L v. 1,64±1,02 nmol/l, 
p<0,001), DHEAs (1,16±1,00 μmol/L v. 2,00±1,08 μmol/L, p=0,008) and an-
drostendione (3,26±3,08 nmol/L v. 5,79±2,82 nmol/L, p=0,004) were signifi-
cantly lower in SSc patients compared to controls. There wasn’t a significant 
difference in serum level of estradiol between groups (p=0,250). Serum levels of 
androstendione negatively correlated with ACA antibodies (r=-0,434, p=0,024). 
Conclusion. Circulating testosterone, anrdostendione i DHEAs levels are de-
creased in post-menopausal patients with SSc compared with healthy post-men-
opausal women. Our study contributed in recent cognitions on altered hormonal 
status in SSc patients. Correlation between androgen compounds androstendione 
and ACA support a protective anti-inflammatory role of androgen steroids in SSc.
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Diet, sun and life style as determinants of vitamin D status
Paul Lips
Department of Internal Medicine/Endocrinology, VU University Medical Center, 
P.O.Box 7057, 1007 MB Amsterdam, the Netherlands
Vitamin D3 is synthesized in the skin under ultraviolet radiation or absorbed 
from the intestine after ingestion of vitamin D containing food or supplements. 
Subsequently, it is hydroxylated in the liver to 25-hydroxyvitamin D (25(OH)D) 
and in the kidney to 1,25-dihydroxyvitamin D (1,25(OH)2D), the active metabo-
lite that stimulates calcium absorption. 
Vitamin D status can be easily assessed by the measurement of the serum con-
centration of 25(OH)D. Vitamin D deficiency (serum 25(OH)D <25 nmol/l) and 
insufficiency (serum 25(OH)D 25-50 nmol/l) are common in European countries 
and elsewhere especially in risk groups, such as young children, pregnant wom-
en, older persons, non-western immigrants, and patients with malabsorption. 
Sunshine exposure only is effective during 6 months of the year, except in (sub)
tropical countries. In autumn and winter most ultraviolet radiation is absorbed in 
the atmosphere. The seasonal variation in serum 25(OH)D is about 25 nmol/l. Vi-
tamin D synthesis in the skin is decreased by skin pigmentation and by the use of 
sunblock. It decreases with age, but the capacity is enormous. Serum 25(OH)D is 
lower in obese persons than in non-obese, due to lower sunshine exposure, lower 
body surface/volume ratio, and storage in fat tissue. Lifestyle variables such as 
clothing negatively influence vitamin D synthesis, and vitamin D deficiency is 
particularly common in the Middle East. The only food that is naturally rich in vi-
tamin D is fatty fish. Eating fish two times per week significantly increases serum 
25(OH)D. Dairy products contain some vitamin D. Margarine is fortified with 
vitamin D in most European countries. Milk is fortified in some countries and 
this has a large influence on serum 25(OH)D as is known from the USA. Milk 
and yoghurt contain much calcium and this has a vitamin D sparing effect. A high 
calcium intake suppresses parathyroid function and this increases the half life of 
serum 25(OH)D. The consumption of cod liver oil can also improve vitamin D 
status considerably, similar to vitamin D supplements. Improvement of vitamin 
D status in the population can best be achieved by a combination of sunshine 
exposure, food fortification and the use of vitamin D supplements. 
14 
D hormone, a full steroidal hormone: recent evidences including 
synergisms with glucocorticoids
*Maurizio Cutolo, **Vanessa Smith, *Bruno Seriolo
*Research Laboratory and Academic Unit of Clinical Rheumatology, Depart-
memnt of Internal Medicine, Universuty of Genova - Italy
**Division of Rheumatology, University of Ghent, Ghent Belgium
Recently, vitamin D deficiency is receiving an increased worldwide attention for 
its involvement in increasing risk for several chronic diseases including many 
cancers, infectious diseases, type-1 diabetes and notably autoimmune rheumatic 
diseases (1). The final active metabolite of vitamin D (1,25(OH)D3) is consid-
ered a steroid hormone for its origin from cholesterol (D-hormone), and like glu-
cocorticoids exerts immunomodulatory activities (GC) (2). Pathysiopathological 
investigations confirm that severe hypovitaminosis D, in genetically predisposed 
subjects, can impair self tolerance and immune responses (like in deficiency on 
glucocorticoids) by compromising the regulation of dendritic cells, regulatory T-
lymphocytes (Tregs), Th1 cells and B cell function (3). However, cross-sectional 
studies have shown that deficient serum levels of vitamin D (25(OH)D) (<20 
ng/mL) are present in a significant percentage, not only in patients with autoim-
mune diseases such as multiple sclerosis (MS), type-1 diabetes, systemic lupus 
erythematosus (SLE) and rheumatoid arthritis (RA), but also in healthy subjects 
(3). As a matter of fact, several data suggest synergistic actions between gluco-
corticoids and vitamin D on immune/inflammatory reactions, for example  asth-
matic patients with a higher serum level of 25(OH)D experienced more signifi-
cant reduction in asthma symptoms score and steroid-sparing effect of SIT (4). 
Steroid-sparing effect correlated with 25(OH)D serum level at baseline and after 
3 months effectively supporting synergistic actions. Interestingly, in other studies 
treatment with 1,25(OH)2D3 potentiated the inhibitory effect of dexametasone 
on IL-17A and TNFalpha production by memory T cells sorted by FACS from 
patients with early RA (5). Furthermore, combination of 1alpha,25-dihydroxyvi-
tamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis, with 
a role for nuclear receptor cross-talk and Erk/Akt signaling (6). Another promi-
nent endocrine role for 1,25(OH)D3 was recently discovered in peripheral es-
trogen metabolism and in estrogen-related cell proliferative activities. 1,25(OH)
D3 decreases the expression of aromatase, the enzyme that generally catalyzes 
the peripheral synthesis of estrogens from androgens, especially in cancer tis-
sues where its intracrine activity is significantly increased, such as in breast and 
prostate cancer, (7). Similar inhibitory effects by 1,25(OH)D3 have been very 
recently reported on cultures of human macrophages with consequent induction 
of a reduced synthesis of cytokines (8). 
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Severe asthma, immune regulation and vitamin D
Catherine Hawrylowicz
MRC and Asthma UK Centre for Allergic Mechanisms of Asthma, King’s 
College London.
Asthma is a chronic inflammatory disease of the conducting airways. The het-
erogeneity of disease is highlighted by the highly variable responses to treat-
ment observed in different patient cohorts. Vitamin D insufficiency is highly 
prevalent worldwide, with estimates in the UK of over 60% insufficiency in the 
summer and autumn months and almost 90% insufficiency in winter and spring. 
It is associated with increased severity and poor control of asthma, including in 
pediatric cohorts. My laboratory has focussed on studies in moderate to severe 
asthma patients who fail to respond to corticosteroids, the primary treatment for 
asthma. Whilst these patients comprise only 5-10% of all asthmatics, they uti-
lise 50% or more of healthcare resources. We have described changes in regula-
tory T cell numbers and function, as well as in CD4+ T cell responses in these 
asthma patients. The steroid enhancing properties of vitamin D in human asthma, 
particularly in steroid refractory asthma, and the immunological basis of these 
effects will be discussed, as will the broader effects of vitamin D in maintain-
ing respiratory health. Ongoing studies combine in vitro laboratory observations, 
with ex vivo correlates in different patient cohorts, and in vivo studies in patients 
following steroid and/or vitamin D treatment.
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Why do T cells express the vitamin D receptor?
Margherita T. Cantorna
Department of Veterinary and Biomedical Sciences, The Pennsylvania State 
University, University Park PA 16802
Diseases where T cell derived IFN-γ and IL-17 is pathologic like inflammatory 
bowel disease are suppressed by active vitamin D (1,25(OH)2D3).  Paradoxically, 
infectious diseases that require these same responses for protection are unaffect-
ed by 1,25(OH)2D3 treatments. Vitamin D receptor (VDR) knockout (KO) CD8+ 
T cells, but not wildtype (WT) CD8+ T cells, induced colitis in Rag KO recipi-
ents. In addition, co-transfer of VDR KO CD8+ T cells with naïve CD4+ T cells 
accelerated colitis development. The more severe colitis was associated with rap-
idly proliferating VDR KO CD8+ cells and increased IFN-γ and IL-17 in the gut. 
Naïve CD8+ VDR KO T cells proliferated more rapidly than WT CD8+ T cells in 
vivo and in vitro. The increased proliferation of VDR KO CD8+ cells was due in 
part to the higher production and response of the VDR KO cells to IL-2. Vitamin 
D is critical in the control of CD8+ T cell proliferation. T cells express low levels 
of the vitamin D receptor until 48h post-stimulation. In addition, CD8+ T cells 
produce the 1-alpha hydroxylase that converts 25(OH)D3 into 1,25(OH)2D3 but 
the enzyme is not induced before 48h of stimulation. T cell regulation by vitamin 
D is a late event. Therefore the data support a new model where vitamin D is 
required to shut off the T cell response. The inability to signal through the VDR 
results in the generation of pathogenic CD8+ T cells from rapidly proliferating 
cells that contribute to the development of inflammation in the gut.  
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Vitamin D and infections
Shoenfeld Yehuda, MD.
FRCP, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center 
(Affiliated to Tel-Aviv University(, Tel-Hashomer 52621, Israel
Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune 
Diseases, Tel-Aviv University, Israel.
In the old days patients with tuberculosis were instructed to be exposed to the sun 
(sent to sanatorium). Eventually it was found that vitamin D secretes catheliciti-
dines which specifically kill mycobacteria. It is believed that common cold and 
pneumonias care more prevalent in winters because in part during the winter we 
are less exposed to sun and have lower levels of vitamin D.
During the years the association of low vitamin D was related to the incidences 
of HBV, HCV, EBV, HIV, upper respiratory viruses and enteric infections, sep-
sis, pneumonia, clostridium, gonorrhea, H1N1, influenza and vaginosis and otitis 
media.
Eventually several interventional studies were carried out and proved the con-
cept; the high dose therapy with Vitamin D may be beneficial in many of the 
above infections.
Vitamin D may be acting as a “panacea antibiotic” and should be used as an 
adjuvant therapy in diverse infections. The mechanisms by which the Vitamin D 
is acting to counteract infections will be delineated. 
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Anti-inflammatory properties of vitamin D receptor agonists
Luciano Adorini
Intercept Pharmaceuticals, New York, NY 10013, USA
1α, 25-dihydroxyvitamin D3 [1,25(OH)2D3], the biologically active form of vita-
min D, is a secosteroid hormone essential for bone and mineral homeostasis. In 
addition, this hormone regulates growth and differentiation of many cell types, 
and has pronounced immune regulatory and anti-inflammatory properties. Vita-
min D receptor (VDR) agonists are real immune modulators, able to promote 
innate immunity and to regulate adaptive immune responses, typically leading to 
anti-inflammatory effects. In addition to exerting direct effects on T cell activa-
tion, VDR agonists markedly modulate the phenotype and function of antigen-
presenting cells, in particular dendritic cells, inducing them to acquire tolerogenic 
properties that favor the induction of regulatory rather than effector T cells. Cur-
rent therapeutic indications include osteoporosis, secondary hyperparathyroidism 
and psoriasis, but the anti-proliferative, pro-differentiative, anti-bacterial, immune 
modulatory and anti-inflammatory properties of VDR agonists could be exploited 
in a variety of additional clinical conditions. In particular, the pleiotropic anti-
inflammatory effects induced by VDR agonists could turn out to be beneficial in 
different pathologies associated with chronic inflammatory responses.
Selected Presentations on the topic
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The effects on T-cell phenotype in patients with systemic lupus ery-
thematosus treated with two different regimens of vitamin D sup-
plementation: an update after a year of therapy
S. Piantoni1,2, A. Zanola1, L. Andreoli1, F. Dall’Ara1,2, M. Scarsi1, M. Cutolo3, 
A. Tincani1
1Rheumatology and Clinical Immunology, Spedali Civili and University of 
Brescia, Italy
2University of Pavia, Italy
3Research Laboratory and Division of Rheumatology, Department of Internal 
Medicine, University of Genova, Italy
Background. Recent studies highlight that Vitamin D (VD) may have an immu-
nomodulatory action on T cells, inhibiting Th1 and Th17 response and enhancing 
Th2 and Treg function. After repeated antigenic presentation, T cells differentiate 
into highly experienced memory T cells (CD45RA+CCR7-) with a peripheral 
expansion of the CD28-T cells, a subpopulation with peculiar effector activities 
(high γ-IFN production). 
Objectives. To verify the effect of VD supplementation on the circulat-
ing levels of effector memory T cells (CD45RA±CCR7-), Treg cells 
(CD25highCD127low),CD28-T cells, and on cytokines production.
Methods. 34 female SLE pts (median age=32.5, range 10-90thpercentile: 24-
40.7) years; median duration of disease=7 (1.3-16.7) years), SLEDAI=2(0-4) 
were enrolled. 17 pts were supplemented with an intensive regimen (IR) of cole-
calciferol (300.000UI for the first month and 50.000UI/monthly as maintenance), 
whereas 17 pts were supplemented with a standard regimen (SR) (25.000UI 
monthly). Phenotypic analysis of peripheral T lymphocyte was evaluated by 
flow-cytometry at baseline and after every 6 months of treatment. The same tech-
nique was used to quantify the intracytoplasmatic production of IL-17, IL-4 and 
γ-IFN from peripheral blood mononuclear cells (PBMC) of 12 pts, stimulated in 
vitro for 5 hours with PMA+ionomycin (5+500 ng/ml). 
Results. After 12 months of treatment, a significant decrease in the number 
of Treg cells was observed (from 8.4 (5.7-13.5) to 6.7 (4.7-14.6)% of CD4+T 
cells; p=0.04) in the entire cohort of pts. Within Treg subtype, an increase in 
peripheral induced (CCR7-) Treg cells was seen, along an increase in the total 
amount of circulating CD4+CD45RA+CCR7-T cells. Moreover, a reduction of 
the CD8+CD28-T cells in SLE pts was demonstrated only in the SR group (Table 
I). In the IR group of pts evaluated for cytokines production (n=6), a reduction 
of γ-IFN/IL-4 (from 9.7 (0.8-18.3) to 6 (1.6-15.1); p=0.04) among CD8+T cells 
was detected. 
Conclusions. VD may promote the enhancement of peripheral induced Treg cells 
and the production of Th2 cytokines. Further studies will be necessary to under-
stand the role of highly experienced memory T cells and of CD28-T cells, whose 
number seems to be inversely correlated with their functional capacity.
Table I.
Cell phenotype IR  
 T0 T12 p
TREG CCR7-(%TREG) 30.9 (15.4-43.1) 34.8 (22.3-63.2) 0.01
T CD4+CD45RA +CCR7-(cell/μl) 6 (2.8-12.5) 9.2 (3.5-33.3) <0.01 
TCD8+CD28-(%CD8+) 24.9 (11.1-49.7) 24.7 (9.7-51.8) ns
Cell phenotype SR  
 T0 T12 p
TREG CCR7-(%TREG) 25.3 (17.3-42.4) 34.7 (19.5-55.5) 0,03
T CD4+CD45RA+CCR7-(cell/μl) 7.7 (2.4-20.9) 16.9 (10.4-51.3) <0.01
TCD8+CD28-(%CD8+) 26.7 (13.7-63.7) 19 (7.4-34.6) 0,01
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Vitamin D serum level correlates with nailfold microangiopathy 
extent in systemic sclerosis patients
*S. Paolino, *A. Sulli, **V. Smith, *B. Seriolo, *G. Botticella, *C. Pizzorni, *A. 
Casabella, *M. Cutolo 
*Research Laboratories and Academic Unit of Clinical Rheumatology, Depart-
ment of Internal Medicine, University of Genova, Genova, Italy 
**Department of Rheumatology, Ghent University Hospital, Ghent, Belgium 
Background. Vitamin D is involved in both innate and adaptive immunity (1). 
In several autoimmune diseases, such as rheumatoid arthritis, systemic lupus 
erythematosus, and undifferentiated connective tissue disease, low 25-hydroxy-
vitamin D [25(OH)D3] serum concentrations correlate with disease activity (1). 
Systemic sclerosis (SSc) is a severe connective tissue disease characterized by 
vascular, immune and fibrotic changes in several internal organs, with a progres-
sive sequence. 
Aim. The aim of the study was to assess whether 25(OH)D3 serum concentra-
tions might be associated with capillaroscopic microvascular markers and clini-
cal features of SSc. 
Methods. 117 SSc patients were enrolled (mean age 67±12SD years; 83% fe-
male; mean disease duration from onset of Raynaud phenomenon 13±13 years). 
All patients were evaluated by nailfold videocapillaroscopy (NVC) to score and 
classify the severity of the microangiopathy (both NVC patterns (“early”, “ac-
tive” and “late”) and microangiopathy evolution score [MES] were assessed), 
as previously reported (2,3). 25(OH)D3 serum levels were evaluated by radio-
immunoassay, and they were classified as normal (>30 ng/ml), insufficient (30 
<25(OH)D3 <10 ng/ml) or deficient (<10 ng/ml) (4). Clinical features of the 
disease were assessed using Medsger’s severity scale (score 0-4) (5). Statistical 
analysis was performed by non parametric tests. 
Results. 25(OH)D3 resulted significantly lower in patients with “late” NVC pat-
tern of microangiopathy in comparison with patients showing either “active” or 
“early” pattern (17.1±12.4 vs 18.2±13.3 vs 20.2±7.4, p<0.005). A negative cor-
relations was found between 25(OH)D3 concentrations and both MES (r=-0,49, 
p<0.003) and peripheral vascular disease according to Medsger scale (r=-0.24, 
p<0.01). There was no significant relationship between serum 25(OH)D3 and 
other clinical features of SSc, including skin, lung, gastrointestinal, renal, heart 
and joint involvement, assessed using the Medsger’s severity scale. Any statisti-
cal significant difference between skin subsets of SSc or gender was not found. 
Conclusion. Our data demonstrate a negative correlation between 25(OH)D3 
serum levels and severity of peripheral microvascular/vascular clinical involve-
ment, in SSc patients. 
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Hypovitaminosis D predicts more aggressive evolution and lower 
response to treatment in early rheumatoid arthritis after 12 months 
of follow-up
Iannuccelli C, Barchetta I, Gerardi MC, Frisenda S, Ceccarelli F, Cavallo G, 
Di Franco M and Valesini G.
Dipartimento di Medicina Interna e Specialità Mediche/Sapienza, Università di Roma 
It has been suggested that the vitamin D active form (1,25 (OH)2D3) has immu-
noregulatory activities, regulating both the innate and adaptive immune respons-
es. Recently, vitamin D has been studied as potential player in the pathogenesis 
of Rheumatoid Arthritis (RA). Indeed, some recent studies showed a negative 
association between serum vitamin D levels and RA activity. Aim of this study 
was to evaluate the correlation between serum vitamin D levels and disease ac-
tivity assessed with clinimetric, biochemical and ultrasound (US) parameters at 
baseline and after a follow-up of 12 months in early RA patients. We recruited 
37 consecutive patients affected by early RA and naïve for treatment among pa-
tients referring to the Early Arthritis Clinic. Hypovitaminosis D was diagnosed 
for 25(OH) vitamin D value <20ng/ml. CRP, ESR, Rheumatoid Factor (RF) and 
anti-citrullinated peptide antibody (ACPA) levels were also measured. Swollen 
and tender joint counts, Disease Activity Score with 28 and 44 joints assess-
ment (DAS28 and DAS44) scores, Simplified Disease Activity Index (SDAI) 
and Clinical Disease Activity Index (CDAI) were assessed at baseline and af-
ter 12 months of treatment. Moreover all patients underwent US assessment for 
synovitis and power Doppler evaluation. At baseline patients with normal levels 
of vitamin D did not show any significant difference in clinimetric, serological 
and US parameters compared to patients with low levels of vitamin D. After a 
12 months follow-up patients with sufficient vitamin D levels at baseline had a 
significant lower disease’s activity and a higher prevalence of remission com-
pared to the group with hypovitaminosis (68% vs 16%, respectively; p<0.001) 
according to DAS28, DAS44, CDAI and SDAI scores (p<0.001 for all indexes). 
Furthermore, normal vitamin D levels were also associated with higher percent-
age of responders to RA treatment (EULAR criteria) compared with vitamin D 
insufficiency (100% vs 75%, p<0.001). The percentage of patients that didn’t 
present a reduction of the US synovitis score was higher in the hypovitaminosis 
patients group. In the present study, early RA subjects with normal vitamin D 
levels showed both a greater reduction of disease activity and higher prevalence 
of response to treatment and of remission compared to patients with hypovita-
minosis D after 12 months of follow-up. Our results provide further support to 
the immunomodulatory role of vitamin D in inflammatory arthritis and indicate 
that baseline hypovitaminosis D may predict a more aggressive evolution of the 
disease and a worse response to treatment. Thus, evaluation of vitamin D serum 
levels and its possible supplementation should become part of the clinical prac-
tice, especially in patients naïve to treatment.
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Target therapies in RA: the place for GC 
Iain B. McInnes
Professor of Medicine, University of Glasgow
Though considered a ‘historic’ therapeutic in the management of rheumatoid ar-
thritis (RA), glucocorticoids (GC) remain at the core of most current therapeutic 
algorithms and guidelines. Their broad immune modulatory effector function 
mediates effective therapeutic benefits in RA manifest in improvement in signs 
and symptoms, reduced erosive progression (i.e. articular damage) and improved 
metrics of quality of life. Their effects on common co-morbidities e.g. in the 
vasculature, bone and brain are less clear reflecting the interaction between tar-
get mediated adverse events and the potentially beneficial effects of relief from 
inflammation in those extra-articular organs thus affected. Remarkably little is 
known of the optimal use of GC in RA – recent studies have demonstrated for 
example that the appropriate choice of timing of delivery can alter the benefit 
profile considerably. Moreover their role as critical co-therapeutics with conven-
tional and also with biologic disease modifying anti-rheumatic drugs (DMARD) 
is relatively little studied – they have tended to be used as an adjunct rather than 
focus of trial design in the last decade. There is now however evidence that they 
can enhance the effect of initial methotrexate administration. In several treat to 
target and strategy trials their use is also in part contributory to the beneficial ef-
fects in some study arms over others. I shall discuss the current use of GC in RA 
management and allude to future areas in which their use, and that of future GC 
like entities may develop over time.
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Membrane receptors of GCs: origin and functional activity
Cindy Strehl
Department of Rheumatology and Clinical Immunology, Charité University 
Medicine (CCM), 10117 Berlin, Germany
Glucocorticoids (GC) are the most common used drugs in the treatment of a 
wide range of rheumatic and other inflammatory diseases. They exert their anti-
inflammatory and immunosuppressive effects primarily via so called genomic 
mechanisms, thus mediated by the cytosolic glucocorticoid receptor (cGR). 
However, rapid effects of GC exist, which are mediated by specific and unspe-
cific non-genomic mechanisms. The membrane-bound glucocorticoid receptor 
(mGR) has been suggested to play an important role by the mediation of specific 
non-genomic GC-action. It has already been shown, that mGRs are up-regulated 
on monocytes of patients with inflammatory diseases, like rheumatoid arthritis, 
and that the frequency of mGR expression positively correlates with the disease 
activity. Furthermore, modified mGR expression has been shown for other in-
flammatory diseases like systemic lupus erythematosus, ankylosing spondylitis 
or after vaccination. Indeed, the clinical relevance of mGR is assumed, but the 
origin and functional activity remained unexplained and has been in focus of 
our study.
We analyzed the origin of mGR protein with the help of RNA-interference tech-
nology. Therefore, we performed a transient (via siRNA) and a stable (shRNA) 
GR knockdown in mGR positive HEK293T cells. The knockdown efficacy was 
verified on mRNA level by RT-qPCR, the reduction of GR protein was inves-
tigated by immunoblot analysis and mGR expression was analysed with high-
sensitive immunofluorescent staining. These experiments demonstrated that, in 
contrast to a transient reduction, a stable knockdown of GR mRNA diminished 
mGR expression.
For functional analysis, LPS stimulated mGR positive human CD14+ monocytes 
were treated with dexamethasone bound to BSA (Dex-BSA). Due to the size this 
substance is membrane-impermeable and thus Dex-BSA selectively activates 
mGR. In order to identify rapid GC effects, PepChip™ array technique was used. 
We were able to show a Dex-BSA specific induction of rapid (de)phosphoryla-
tion processes mediated by different kinases. A number of MAP-kinases, includ-
ing p38 MAPK, were identified to show an increased phosphorylation according 
to Dex-BSA treatment.
A genome analysis via microarray also revealed that Dex-BSA altered gene ex-
pression. A functional classification into biological processes of identified genes 
via Panther database demonstrated that processes of signal transduction and me-
tabolism are most affected by selective mGR activation. 
Altogether, we were able to demonstrate that there is only one gene encoding 
for both, the cGR as well as for the mGR. Furthermore, an activation of mGR 
by membrane-impermeable Dex-BSA revealed that external signals were trans-
ferred in the cell via rapid (de)phosphorylation processes by the mean of kinases. 
Additionally, it has been shown that an activation of the mGR results in an al-
tered gene expression. This is the evidence of the functional activity of the mGR. 
However, these effects need to be further investigated in order to identify mGR 
signalling pathways and their target genes more in detail. Nevertheless, the hu-
man mGR represents an interesting target for optimised treatment strategies in 
case of rheumatic or other inflammatory diseases.
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Glucocorticoid metabolism and inflammation: crucial interactions
Mark Cooper
ANZAC Research Institute, University of Sydney, Australia.
The anti-inflammatory actions of endogenous and exogenous glucocorticoids are 
well established. Until now, most attention has been focused on the level of glu-
cocorticoids in the circulation. However, the level of glucocorticoids within cells 
and tissues is also regulated by local glucocorticoid metabolism. The most im-
portant enzymes regulating local glucocorticoid metabolism are the 11b-hydrox-
ysteroid dehydrogenases (11b-HSDs). The 11b-HSD type 1 enzyme converts in-
active cortisone to active cortisol whereas the 11b-HSD type 2 enzyme converts 
cortisol to cortisone. 11b-HSD1 is expressed in a range of tissues including bone 
and synovium. Expression in vitro and in vivo appears to increase in response 
to proinflammatory cytokines such as TNF-α and IL-1b. In rheumatoid arthritis 
11b-HSD1 activity appears to also correlate with the level of inflammation but 
it is possible that the relative level of expression is lower than that expected for 
the degree of inflammation. Global deletion of 11b-HSD1 expression in mice 
results in an exaggerated inflammatory response to experimental arthritis and 
an abnormal bone phenotype. The inactivating enzyme 11b-HSD2 has also been 
identified in macrophages within the rheumatoid synovium along with peripheral 
blood mononuclear cells in individuals with rheumatoid arthritis. Expression of 
this enzyme outside of the classical mineralocorticoid receptor positive tissues 
is highly unusual but would be expected to confer glucocorticoid resistance to 
immune cells where expressed. The exact function of 11b-HSD2 within the joint 
has not been fully explored. Current studies are exploring the specific role of 
11b-HSD1 and 11b-HSD2 in inflammatory disease in humans and in particular 
whether an abnormal expression of these enzymes can predispose to the develop-
ment or persistence of inflammation. 
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GC and microRNA: a new discovered cross talk
*Nancy L. Krett, *Michael Tessel, **Ashley Benham, **Preethi Gunaratne and 
*Steven T. Rosen
*Robert H. Lurie Comprehensive Cancer Center, Northwestern University, 
Chicago, IL, USA
**Department of Biology and Biochemistry, University of Houston, Houston, 
TX, IL, USA
Glucocorticoids (GCs) are widely used in the treatment of inflammatory diseases 
and in hematological malignancies such as multiple myeloma (MM). However, 
the development of resistance to GCs limits their clinical utility and understand-
ing the mechanisms of GC resistance may provide additional therapeutic ap-
proaches for improved clinical outcomes. We have examined the mechanisms of 
GC resistance in models of multiple myeloma (MM) and the loss of glucocor-
ticoid receptor-alpha (GR) expression is frequently the basis for resistance. We 
have previously developed cell lines from a MM patient who had been treated 
with GCs and become resistant to that treatment. We have reported that the re-
sponse to GCs is dependent on an active GR which is present in the GC sensitive 
cell line (MM.1S) and down-regulated in the GC resistant derivatives MM.1Re 
and MM.1RL. We determined that regulation of GR expression occurs at a post-
transcriptional level and further examined the involvement of microRNAs (miR-
NAs) in this process. MiRNAs predominantly bind sites in the 3’ untranslated 
region (UTR) of coding genes to mediate post-transcriptional gene silencing. 
Here we observed that luciferase reporters containing the 3’-UTR of GR are sig-
nificantly repressed in MM.1R cells when compared to MM.1S cells. To identify 
specific miRNAs involved in regulation of GR, we sequenced the small RNA 
population in MM.1S, MM.1Re and MM.1RL cells using next generation se-
quencing. We identified candidate miRNAs through potential binding sites in the 
GR 3’ UTR and through differential expression in GC-sensitive versus –resistant 
MM cells. We manipulated the expression of candidate miRNAs through over-
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expression of candidate miRNAs mimics predicted to target GR. We identified 
miR-130b as a miRNA that is consistently up-regulated in MM.1R cells and able 
to repress endogenous GR protein levels in MM.1S and also repress a luciferase 
reporter containing the 3’-UTR of GR-alpha. In addition we show that GC treat-
ment of MM.1S transfected with hsa-miR-130b mimics induces resistance to GC 
actions, reduces the levels of GC inducible gene GILZ, a downstream target of 
GR, and inhibits apoptosis. We conclude that differential expression of miRNAs 
play a role in the regulation of GR expression contributing to GC resistance.
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Anti-cytokine therapy affecting pain-related central nervous system 
activity  
Georg Schett
Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, 
Germany
Cytokine blocking agents have substantially improved our therapeutic armamen-
tarium to treat inflammatory diseases such as rheumatoid arthritis (RA). Although 
inflammation in diseases like RA depends on the expression of a multitude of 
cytokines, chemokines and growth factors, only few of them have emerged as 
major therapeutic targets. In particular, neutralization of tumor necrosis factor 
α (TNF-α) achieves very profound and fast amelioration of some clinical symp-
toms of arthritis, which appears to precede its anti-inflammatory effect. There has 
always been a gap in explaining of how TNF-α blockade can so rapidly affect the 
patients’ disease state, considering that RA is a very chronic condition. We thus 
hypothesized that blockade of TNF-α acts through the central nervous system 
(CNS) before directly affecting joint inflammation. By use of functional mag-
netic resonance imaging (fMRI), we demonstrate that neutralization of TNF-α 
blocks nociceptive CNS activity in the thalamus and somatosensoric cortex but 
also the activation of the limbic system as early as 24 hours after the onset of 
treatment. Moreover, arthritic mice overexpressing human TNF-α showed an al-
tered pain behavior and a more intensive, widespread and prolonged brain activ-
ity upon nociceptive stimuli as compared to wild-type mice. Similar to humans, 
these changes as well as the rewiring of CNS activity resulting in tight clustering 
in the thalamus were rapidly reversed after neutralization of TNF-α. These re-
sults suggest that neutralization of TNF-α affects nociceptive brain activity in the 
context of arthritis, long before it achieves anti-inflammatory effects in the joints. 
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Circadian CLOCK-mediated HPA axis and gene-specific regula-
tion of peripheral glucocorticoid receptor transcriptional activity by 
acetylation 
George P. Chrousos
First Department of Pediatrics, University of Athens Medical School, “Aghia 
Sophia” Children’s Hospital, Athens, 11527, Greece 
Circulating cortisol concentrations fluctuate diurnally under the control of the 
“master” circadian CLOCK system located in the hypothalamus, while we re-
cently reported that the peripheral “slave” circadian CLOCK system regulates 
the transcriptional activity of the glucocorticoid receptor (GR) by acetylating it 
at local target tissues. To examine Clock-mediated GR acetylation and circadian 
changes in the sensitivity of peripheral target tissues to glucocorticoids (GCs) in 
humans, we examined the acetylation of the GR and the mRNA expression of the 
GR, Clock, Bmal1, and 8 known GC-responsive (4 transactivated and 4 transre-
pressed) genes in peripheral blood mononuclear cells (PBMCs) obtained from 10 
healthy subjects at 8 am and at 8 pm. GR acetylation levels were higher in the 
morning than in the evening, in synchrony with fluctuations of Clock and Bmal1 
mRNAs and the levels of circulating ACTH and cortisol. The mRNA expression 
of certain genes regulated positively (GILZ and tristetraprolin) or negatively (in-
terferon gamma, IL-1alpha and IL-12 p40) by GCs demonstrated the expected 
concomitant diurnal fluctuations, while, surprisingly, those of other such genes 
(Annexin A1, dual phosphatase 1 and TNFalpha) did not fluctuate. To further ex-
amine details of the acetylation-mediated regulation of GC-responsive genes, we 
obtained PBMCs from 6 additional healthy subjects and cultured them for 24 h 
ex vivo in the absence or presence of added hydrocortisone, assuming continuing 
oscillation of the cellular CLOCK system. In these cells, hydrocortisone-induced 
mRNA expression of the GC-responsive genes previously found to not corre-
late with circulating cortisol in vivo demonstrated circadian fluctuation, mirror-
ing the levels of GR acetylation and Clock mRNA expression, while that of the 
genes that correlated with circulating cortisol in vivo did not show fluctuation ex 
vivo. Knockdown of Clock by its siRNA in cultured PBMCs abolished this gene-
specific fluctuation of GR transcriptional activity. These results suggest that the 
transcriptional activity of the human GR is moderated in a gene-specific fashion 
through circadian GR acetylation by the peripheral CLOCK, counteracting the 
transcriptional effect of circulating cortisol. Coordinated regulation of GC action 
at target tissues by circulating cortisol and peripheral CLOCK-mediated epige-
netic modulation of the GR appears to be essential for the maintenance of GC 
homeostasis in man. Uncoupling of such coordination might lead to increased 
exposure of tissues to glucocorticoids and pathologies related to functional hy-
percortisolism.
Selected Presentations on the topic
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Does adrenocortical androgenic and glucocorticoid imbalance occur 
before onset of rheumatoid arthritis (pre-RA) in women: results of 
a controlled cohort study
*Alfonse T. Masi, **Maurizio Cutolo, ***Richard Imrich, *Azeem A. Rehman
*University of Illinois College of Medicine (UICOMP), Peoria, IL 61656, USA
**Research Laboratory and Academic Unit of Clinical Rheumatology, Depart-
ment of Internal Medicine DiMI, Division of Rheumatology, University of 
Genova, Italy
***Center for Molecular Medicine, Institute of Experimental Endocrinology, 
Slovak Academy of Sciences, Slovak Republic
Background. Polymorphic variations of the adrenal cortex may influence in-
trinsic susceptibility to neuroendocrine-immune (NEI) disease risk, including 
rheumatoid arthritis (RA).
Objective. The aim of this study was twofold, initially to identify literature evi-
dence of adrenocortical polymorphisms, and additionally to analyze baseline 
serum levels of DHEAS (zona reticularis androgenic marker) and cortisol (zona 
fasciculata glucocorticoid) steroids in women, before onset of rheumatoid arthri-
tis (pre-RA) in a controlled cohort study.
Study Methods. PubMed literature search included hypo- and hyper-function/
plasia of the adrenal cortex, its hypothalamic-pituitary (HP) control, genetic 
mechanisms (SF-1 and DAX-1), zonal steroidogenic molecular and morphologic 
polymorphism, adrenarche, and aging. Analysis involved the 1974 CLUE 1 co-
hort, which enrolled 12,381 Caucasian women of Washington County, MD, from 
whom 36 baseline pre-RA developed ACR-positive RA, after 3 to 18 (median 12) 
yrs. Four CN were closely matched to each pre-RA. Pearson bivariate correla-
tions and scatterplots of baseline DHEAS and cortisol levels were analyzed, us-
ing z-scores specific to laboratory batch assays. Multivariate regression analysis 
(MRA) estimated the ability of cortisol to independently predict the dependent 
DHEAS outcome values in the study groups (pre-RA vs CN) and by other subject 
stratifications.
Results. Complex heritability was associated with a greater variability in serum 
adrenocortical androgens (AA), including DHEA, its sulfate (DHEAS), during 
development (adrenarche) and aging, than cortisol. Interactions of steroidogenic 
factor (SF-1) and DAX-1 (i.e., dosage-sensitive sex reversal, adrenal hypoplasia 
critical region, on chromosome X, gene 1) genes are believed to influence hyper-
glucocorticoid synthesis in rats, and DAX-1-deficient mice may be predisposed 
to adrenal failure in aging.
Baseline serum cortisol and DHEAS z-scores correlated negatively (r=-0.725) 
in 12 pre-RA who had pre-menopausal onset, but positively (r=0.448) in 23 
cases with post-menopausal onset (p<0.001). MRA of the pre-RA hormonal 
data confirmed the opposite correlations between pre- vs post-menopausal on-
sets (p=0.009). Opposite correlations (p=0.002) were also observed between the 
16 younger cases who entered the cohort under age 44 years (r=-0.501) vs 20 
older pre-RA (r=0.512), but did not occur between their respective matched 64 
younger (r=0.055) and 80 older (r=-0.100) control subjects (p=0.363).
Conclusions. A minority subgroup of women may have adrenocortical andro-
genic and glucocorticoid imbalance before onset of RA, which deserves further 
study.
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Disease-modifying effects of glucocorticoids in the treatment of 
rheumatoid arthritis: new evidence
Johannes WJ Bijlsma
University Medical Center Utrecht, NL In the Utrecht region, the Netherlands
The so called CAMERA (Computer Assisted Management in Early Rheumatoid 
Arthritis) II study has recently been performed, in which all patients were treated 
with the computer guided monthly tight control scheme, aiming for remission, 
with increasing dosages of methotrexate (MTX), but randomized to addition of 
10mg prednisone/daily or of placebo for study duration of 24 months. All pa-
tients had early RA according to the ACR 1987 criteria, with disease duration 
less than one year, DMARD and GC naïve. Treatment was started with MTX 10 
mg/week, if necessary increasing every month with 5 mg up till 30 mg/week; if 
no remission was reached adalimumab 40 mg/2 weeks was added. In addition 
either 10 mg prednisone or placebo was added. When remission was reached the 
treatment was reduced again. 235 patients were randomized 60% women; mean 
age 54 years; 68% rheumatoid factor positive; mean ESR 35; mean 16 tender 
and 15 swollen joints. Primary outcome after two years was the absolute erosion 
score; this primary outcome was met in favor of the GC group. Importantly, after 
two years 70% of the patients treated with tight control MTX had no erosions, in 
the patients treated with additional prednisone this percentage increased to 82. 
As expected, clinical variables, as well as CRP and ESR, improved during the 
first 6 months more in the prednisone than in the placebo group; after 6 months 
this was similar in all groups. The definition of remission that was used in the 
CAMERA II study was: zero swollen joints and 2 out of 3: tender joints 3 or less, 
ESR 20 or less, VAS general health (0-100) 20 or less. Remission was reached 
in the prednisone group in 72%, versus 61% in placebo group; the start of the 
remission was earlier in the prednisone group (6 versus 11 months). If oral MTX 
was not well tolerated, or not effective enough, MTX was given subcutaneous; 
if remission was not reached adalumimab was added as an additional step. In 
the prednisone group only 26 patients needed sc MTX versus 60 in the placebo 
group; the difference in use of biologicals was even more impressive: only 16 
in the prednisone group versus 42 in the placebo group. A detailed register of 
adverse events was kept at each monthly visit; there was no increase in infections 
in the prednisone group, no increase in cardiovascular events, diabetes mellitus, 
hypertension or fractures. There were significantly less gastrointestinal adverse 
events in the prednisone group, especially nausea (51 in the prednisone group 
versus 152 in the placebo group), and remarkably less liver function disturbances 
(ALAT above upper limit of normal): 87 in the placebo group versus 30 in the 
prednisone group. GC seemed to improve the gastrointestinal tolerance of MTX. 
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Bone safety by low-dose glucocorticoids in rheumatic diseases
Kenneth Saag
Department of Medicine, Division of Clinical Immunology and Rheumatology,  
The University of Alabama at Birmingham, AL, USA
At high doses glucocorticoids produce predictable loss of bone via direct del-
eterious effects on osteoblasts, osteocytes, and osteoclasts. At lower doses, the 
evidence is less robust, but it continues to support toxicity to bone, in a dose 
dependent fashion. In contrast to their toxic effect to bone, glucocorticoids also 
suppress the pro-inflammatory cytokines that contribute to bone loss and these 
effects potentially partially counter their negative effects on bone. The major-
ity of data on the glucocorticoid effects on bone come from observational data; 
many studies examining data other than in RA. The association of glucocorti-
coids with bone loss using this data is prone to bias, such as confounding by 
indication and diagnostic detection bias. Several randomized controlled trials of 
glucocorticoids also have examined this issue and the findings have been less 
conclusive of significant bone issues. However, these RCTs are underpowered to 
examine this question. A variety of therapeutic agents are approved for preven-
tion and treatment of glucocorticoid induced osteoporosis. The timing of ini-
tiation, sequencing, and long-term safety of these drugs is a subject of debate. 
Despite international guidelines, many RA patients on glucocorticoids do not 
receive bone protective agents.
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Two decades of experience with the COBRA study
Maarten Boers, MSc, MD, PhD, Professor of Clinical Epidemiology
Department of Epidemiology and Biostatistics, VU University Medical Center, 
Amsterdam, Netherlands
The lofty title of this presentation is based on the fact that the design of the CO-
BRA (Dutch: COmbinatietherapie Bij RA) study started in 1990, recruitment in 
1992. The data were published in 1997, and many spinoff and follow up studies 
followed. 
This presentation gives a bird’s eye overview of the original trial results, the 
long-term follow up, and results of replications and variations of the treatment 
regimen. 
The COBRA regimen comprises the combination of oral prednisolone, metho-
trexate and sulfasalazine:
1.	 an oral prednisolone pulse in a schedule that starts with 60 mg/d in the first 
week, with weekly steps down (week 2-6: 40; 30; 20; 15; 10 mg/d) to 7,5 
mg/d in week 7, after which the dose is kept constant until month 6;
2.	 methotrexate, 7,5 mg/w;
3.	 sulfasalazine, 2 g/d (1g/d in the first 2 weeks).
In the original trial, prednisolone was tapered to 0 in 6 weeks starting at month 
6, and methotrexate in 4 weeks after month 9. Drugs were reinstituted if a flare 
occurred.
COBRA was found to be superior to sulfasalazine monotherapy in signs and 
symptoms in the first 6 months, and in damage progression and physical function 
in the first 12 months and beyond (1). In addition, COBRA had less side effects 
and it dominated the control arm in terms of direct and indirect costs (2, 3). 
Two follow up studies (at 5 and 11 years) with patients treated according to phy-
sician preference suggest the initial structural benefit was maintained without an 
increase in toxicity (4, 5). 
The BeSt (Dutch: BehandelStrategieën bij RA) study compared 4 regimens: se-
quential monotherapy, step-up, COBRA, and initial high dose methotrexate with 
infliximab. Both in the initial trial and in subsequent follow up studies, the latter 
two arms were superior in terms of clinical and radiological results, with differ-
ences between groups gradually becoming less prominent. (6, 7). Importantly, 
COBRA was indistinguishable from high dose methotrexate and inflximab in 
terms of clinical and radiological results, at a fraction of the price of treatment (8).
Despite these impressive results, implementation has been sluggish, no doubt 
partially due to relentless marketing of biological agents. However, in an imple-
mentation study we found and addressed several barriers, mostly on the physician 
side (9-11). For the patients we produced information materials and support, and 
for the physicians a collection of supporting literature as well as templates for 
prescription freely available in Dutch and English (see: www.cobratherapy.nl). 
In other centers, René Westhovens in Leuven, Belgium was one of the origi-
nal trial center coordinators who has published on the efficacy of COBRA in 
routine practice (12). In Bristol, UK John Kirwan has implemented COBRA in 
the routine care of patients that meet the inclusion criteria of the trial (personal 
communication). Many centers now apply modified step-down schedules in their 
routine care, but until recently evidence for their efficacy was lacking. We re-
cently published the half-year results of the ‘COBRA-light’ trial, that suggests 
a modified step-down regime (starting with 30 mg of prednisolone) combined 
with high-dose methotrexate has similar clinical efficacy compared to the full 
COBRA schedule (13). Analysis of the 1-year results (that include radiographs) 
is currently underway.
On the more intensive side, we performed a small pilot study that suggested the 
efficacy of COBRA could be much enhanced by increasing the methotrexate and 
adding hydroxychloroquine (14). Unfortunately we were unable to date to secure 
funding for a larger study.
In summary, the COBRA regimen has proved to be highly effective in the short 
and long run, with a very acceptable safety profile. Its equivalence to initial high-
dose methotrexate plus infliximab has no doubt helped to put a hold on the steady 
advance of biological therapy in early disease. Implementation has been sluggish, 
but appears to be gathering speed. Current studies are aimed at optimization.
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The efficacy, effectiveness, and safety of 3mg/day prednisone for 
initial and long-term management of rheumatoid arthritis
Theodore Pincus
NYU-Hospital for Joint Diseases, New York, NY, USA
Objectives. Prednisone treatment in 308 patients with rheumatoid arthritis (RA) 
of one academic rheumatologist was analyzed from 1980-2004 for initial dose, 
long-term effectiveness, and adverse events. In the early 2000s, a randomized, 
double-blind, placebo-controlled, withdrawal clinical trial was conducted of 
prednisone <5 mg/day versus placebo. 
Patients and Methods. A database of all patient visits included medications, 
adverse events, and patient self-report multidimensional health assessment ques-
tionnaire (MDHAQ) scores for physical function, pain, and routine assessment of 
patient index data (RAPID3), at each visit. Data were analyzed in 5-year periods, 
1980-84, 1985-99, 1990-94, 1995-99, and 2000-04. The randomized, double-
blind, placebo-controlled, withdrawal clinical trial was conducted in patients 
with stable clinical status over 12 weeks while taking 1-4mg prednisone/day in 
three phases: a) “equivalence” - 1-mg tablets taken for 12 weeks, to ascertain 
efficacy versus the patient’s usual prednisone tablets prior to randomization; b) 
“transfer” - substitution of a 1-mg prednisone or identical placebo tablet at a rate 
of a single 1-mg tablet every 4 weeks (over 0-12 weeks) to the same number as 
baseline prednisone; c) “comparison” - observation over 24 subsequent weeks 
taking the same number of either placebo or prednisone tablets as at baseline. The 
primary outcome was withdrawal due to patient-reported lack of efficacy versus 
continuation in the trial for 24 weeks. 
Results. Mean initial prednisone doses were 10.3, 6.5, 5.1, 4.1 and 3.6 mg/day in 
1980-84, 1985-99, 1990-94, 1995-99, and 2000-04. The proportions of patients 
whose initial prednisone doses were >5 mg/day were 49%, 16%, 7%, 7% and 
3% of patients, 5 mg/day in 51%, 80%, 70%, 26% and 10%, and <5 mg/day 
in 0, 4%, 23%, 67% and 86% in the respective 5 year periods. Most patients 
received early concomitant methotrexate after 1990. Patients treated with >5 mg/
day had higher MDHAQ scores, reflecting poorer clinical status. MDHAQ scores 
were improved similarly in patients treated with <5 or >5 mg/day, maintained 
over >8 years. Primary adverse events were skin-thinning and bruising. New 
hypertension, diabetes and cataracts were seen in <10%. In the randomized trial, 
31 patients were randomized, 15 to prednisone and 16 to placebo, with 3 ad-
ministrative discontinuations. In “intent-to-treat” analyses, 3/15 prednisone and 
11/16 placebo participants withdrew (p=0.03). Among participants eligible for 
the primary outcome of withdrawal for lack of efficacy, 3/13 prednisone versus 
11/15 placebo participants withdrew (p=0.02). No meaningful adverse events 
were reported, as anticipated. 
Conclusion. The data suggest that many patients with RA might be treated ef-
fectively with initial and long-term prednisone <5 mg/day. The efficacy of 3 mg 
prednisone/day was documented in a small clinical trial, with statistically signifi-
cant results suggesting robust treatment effects.
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Glucocorticoid combination with biologics in JA: recommendations 
and guidelines
Alberto Martini
University of Genoa and G. Gaslini Institute, Genoa, Italy
Glucocorticoids have few indications in juvenile idiopathic arthritis given that 
their several side effects including growth arrest or retardation may outweigh 
any benefits on articular disease. Moderate or high-dose systemic corticosteroid 
therapy are reserved for patients with systemic JIA whose disease is not con-
trolled by non-steroidal anti-inflammatory drugs although the recent introduction 
of other effective therapies, such as interlukin-1 and interleukin-6 inhibitors, has 
greatly reduced their indication. In the other juvenile idiopathic arthritis catego-
ries a course of low-dose prednisone may be considered for reducing pain and 
stiffness in patients with severe polyarthritis unresponsive to other therapies or 
while awaiting the full therapeutic effect of a recently initiated second-line agent. 
Intra-articular steroid injections with triamcinolone hexacetonide are frequently 
needed at disease onset or during disease course especially to prevent deformities 
secondary to joint contracture
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Glucocorticoid sparing effect of TNF inhibitors in RA
Maya Buch
Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of  Leeds, 
UK
Tumour necrosis factor inhibitors (TNFi) heralded the highly successful biologi-
cal DMARD era in the management of rheumatoid arthritis (RA). Glucocorti-
coids (GC) however remain a commonly used adjunctive medication. Whilst ef-
fective and shown to be safe in moderate doses, GCs are nonetheless associated 
with safety concerns, particularly in certain populations such as the elderly and 
those with co-morbidity. The success of TNFi has enabled the evaluation of con-
comitant medication, including the use of GC. This talk will review the literature 
on GC use with TNFi in both trials and real-life practice; discuss whether initia-
tion of TNFi has been associated with decreased GC utilisation and the potential 
benefits of this. Guidance on how this may be undertaken will also be discussed.
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Effects of glucocorticoids on bone in RA, the BeSt study
Prof Dr Willem F. Lems
VUmc, Amsterdam, the Netherlands 
Until recently, the majority of RA-patients was treated with DMARD-monother-
apy, resulting in joint erosions and cartilage loss in many patients. A two-fold 
increase in the prevalence of osteoporosis, defined as a T-score <-2.5, was found 
in a large Norwegian study in RA-patients versus healthy controls (Haugeberg G, 
Arthritis Rheum 2000). In line with that, the risk of a having a vertebral fracture 
was doubled in RA-patients (Orstavik RE, Arch Int Med 2004). Nowadays it is 
thought that in patients with systemic inflammation, bone resorption is upregu-
lated, modulated by changes in RANKl/OPG, while the inhibition of the Wnt-
pathway induces depressed bone formation (Schett G, Ann Rheum Dis 2010). 
Theoretically, adequate suppression of systemic inflammation in RA might 
have bone sparing effects. This has been investigated in the BeSt study, a novel 
study design comparing four different treatment strategies in which treatment 
adjustments were made continuously when low disease activity, defined as dis-
ease activity score (DAS) <2.4, was not reached in patients with recent-onset 
RA (Goekoop-Ruiterman YP, Ann Int Med 2007). The treatment strategies were: 
group 1. sequential monotherapy starting with methotrexate (MTX), group 2. 
step-up combination therapy starting also with MTX, group 3. initial combina-
tion therapy with MTX, sulphasalazine and quickly tapered high dose of pred-
nisone, and group 4. initial combination therapy with MTX and tumor necrosis 
factor alpha (TNF-α) inhibitor infliximab. After 2 years of treat to target therapy, 
BMD decreased at the hips by -1.1% (group 1), -0.2% (group 2), -0.2% (group 
3) and -0.6% (group 4). At the lumbar spine, the bone loss was -0.4%, -1.6%, 
-0.5% and -1.0%, respectively (Guler-Yuksel M, Ann Int Dis 2009). We conclud-
ed that generalized bone loss was limited in all 4 groups of patients and, that the 
generalized bone loss was not higher in patients initially treated with high dose 
prednisone. In addition, radiological joint damage was low in all 4 groups. This 
clearly suggests that the negative effect of glucocorticoids (GC) on bone should 
be outweighted against the strong anti-inflammatory effects of GC on bone (Vis 
et al., Osteoporosis Int 2013). Unfortunately, since the BEST-study was a treat 
to target study, several treatment options were prescribed to patients who do not 
have low disease activity: it was not a randomized controlled trial comparing the 
effects of prednisone versus placebo. However, it has recently been demonstrated 
that prednisone 10 mg per day in early RA-patients treated with MTX, has a 
positive effect not only on disease activity, but also on radiological joint damage 
(Bakker MF, Ann Int Med 2012). In conclusion, the BEST-study was among the 
first modern treat to target studies that showed that the use of GC may not be 
harmful to the bone.  
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The combination glucocorticoid-adalimumab-methotrexate as  
induction therapy in early aggressive rheumatoid arthritis
Carlomaurizio Montecucco, Roberto Caporali, CURE study investigators
Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation, University 
of Pavia, Pavia, Italy
 
Early remission is the treatment goal in rheumatoid arthritis (RA). Clinical trials 
indicate that it can be more commonly obtained by combination therapies either 
including different traditional DMARDs or DMARDs with a biologic agent or 
DMARDs with high-dose, short-term glucocorticoids (COBRA regimen). Com-
bination therapies can be effective using a “tight control” step-up strategy and 
also as starting treatment to take more advantage of the window of opportunity.
In patients with early aggressive RA, combination therapy with biologic agents 
and methotrexate (MTX) leads to higher remission rates when compared with 
mono-therapy regimens. Moreover, it has been clearly demonstrated that a short-
term aggressive treatment with high dose prednisone associated to traditional 
DMARDs may lead to long-term benefits and also to a very high remission rate 
in a pilot study.
We designed a prospective controlled study in order to evaluate the effect on re-
mission rate and remission duration of an intensive induction treatment including 
high-dose prednisone (COBRA-like) in addition to both MTX and Adalimumab. 
Two hundred and forty-four subjects with early (>6 weeks, <1 year), MTX-naive 
RA were enrolled from 20 Italian tertiary referral centers. All patients had active, 
aggressive disease with >8 swollen and tender joints, CRP >15 mg/L or ESR 
≥28 mm/h, and ≥1 joint erosion or positive test for rheumatoid factor or anti-
citrullinated peptide antibodies. Patients were randomly selected to receive either 
prednisone (60 mg/day tapered to 6.25 mg in 6 weeks and to 0 in 6 months) or 
placebo in association with MTX 20 mg/week and Adalimumab 40mg eow. Re-
mission rate at 12 months was the primary outcome. Those patients who achieved 
remission at the end of month 12, were followed up for another 12 months-period 
while receiving only MTX as maintenance therapy. Persistence of remission after 
Adalimumab discontinuation was a secondary objective of the study. 
Enrollment was accomplished at the end of 2012 and a complete evaluation of 
the primary endpoint will become available in February 2014. An interim analy-
sis at 6 months was carried out (in a blind way, as safety check) on the first 
122 patients enrolled. The analysis showed a frequency of withdrawal for severe 
adverse events (mostly due to MTX-related toxicity) <10%, whilst the overall 
remission rate exceeded 60%.  
To date, no clinical studies have been reported on high-dose glucocorticoids in 
combination with biologic agents as treatment strategy for induction of remission 
and maintenance. Our preliminary report suggests that this approach might be 
effective with an acceptable safety profile.
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Anti-TNF therapy improves the hypothalamic-pituitary-adrenal axis
Piercarlo Sarzi-Puttini, Fabiola Atzeni 
Rheumatology Unit, University Hospital L. Sacco, Milan, Italy
TNF-α, a potent cytokine produced by monocytes, macrophages, B and T cells, 
and fibroblasts plays a key role in RA and can change the balance of T regulatory 
cells and control acute immunological responses, and interferes with neuro-endo-
crine axes. RA patients with high TNF levels have cortisol and ACTH levels that 
are insufficient in relation to inflammation. The reason for this is unknown, but 
continuous TNF and interleukin (IL)-6 stimulation of the hypothalamus induces 
a hypothalamic-pituitary adaptation that annuls organ responses: cytokine levels 
remain high, whereas hormone concentrations are at most normal. The lower lev-
els of adrenal hormones can be attributed to TNF’s direct inhibitory effect on the 
expression of the steroidogenic acute regulatory protein and the ACTH-stimulat-
ed expression of the steroidogenic enzymes P450ssc, P450c21, and P450c11 in 
830
II. Clinical Issues  5th international Conference on NeuroEndocrine Immunology in Rheumatic Diseases
adrenocortical cells. A recent study has demonstrated a rapid increase in ACTH 
levels in patients with prednisolone-naïve RA after anti-TNF antibody injections; 
in relation to serum TNF levels, ACTH and cortisol levels continuously increased 
during the 12 weeks of anti-TNF treatment. Furthermore, the decrease in the 
serum cortisol to ACTH ratio suggested the sensitisation of ACTH secretion was 
associated with a relative increase in ACTH. Long-term therapy with anti-TNF 
sensitises the pituitary gland and improves adrenal androgen secretion in patients 
with prednisolone-naïve RA, which indicates the normalisation of the HPA axis 
and must therefore be considered evidence of the additional anti-inflammatory 
effect of anti-TNF treatment in RA patients. 
We have investigated the role of HPA axis hormones as predictors of immedi-
ate clinical improvement during anti-TNF antibody therapy, and found that the 
improvement in RA responders may be related to an increase in serum cortisol 
levels because TNF inhibits the adrenal conversion of 17OHP to cortisol. These 
findings indicate that the rapid benefit of anti-TNF agents in some patients is 
probably due to the resoration of P450c21, and P450c11 in adrenocortical cells.
In conclusion, long-term anti-TNF therapy restores the hormonal pathway, lead-
ing to the normalisation of hormone levels/ratios that is associated with a rapid 
clinical improvement of RA.
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Do biologic drugs induce a reduction in steroid burden in systemic 
lupus erythematosus?
Andrea Doria
Division of Rheumatology, Department of Medicine, University of Padova, Italy
Different patterns of disease activity were identified in SLE patients including 
relapsing remitting, long quiescent and chronic active pattern.
Clinical quiescent disease can be observed in approximately 30-40% of cases 
and chronic active and relapsing remitting disease in the other 60-70%. The per-
sistence of disease activity has some important consequences: first of all it leads 
to organ damage which we know to predict more damage and death in SLE. One 
of the major determinants of damage is use of corticosteroids, especially when 
they are administerd at high dosage.  It has been shown that the Hazard ratio for 
organ damage progressively increases according to the progressive increase of 
cumulative average dose of prednisone. Thus, to stop corticosteroids or to reduce 
their dosage are unmet needs in SLE.
Belimumab is a fully human monoclonal antibody which selectively targets and 
inhibits soluble B lymphocyte stimulator (BLyS), also called B activating Factor 
(BAFF). Inhibition of BLyS can result in autoreactive B-cell apoptosis. Beli-
mumab obtained the registration for lupus by Food and Drugs Administration 
and by European Medicine Agency.
In phase III randomized control trials, BLISS-52 which enrolled 865 patients, 
and BLISS-76 which enrolled 819 patients, patients with mild-to-moderate dis-
ease activity who were stable in their baseline treatment for at least 6 months 
were randomized to receive placebo, Belimumab 1 mg/kg or Belimumab 10  mg/
kg plus the standard of care.
Both studies met their primary end-points showing a higher frequency of clinical 
response in patients treated with Belimumab in addition to standard of care com-
pared with those treated with standard of care alone. Belimumab plus standard 
of care was generally well tolerated, with a safety profile comparable to that of 
placebo plus standard of care.
Notably, in BLISS 52 a significantly higher response was observed at each visit 
until week 52, starting at week 16 whith a dose related response. In addition, 
the probability of developing a flare was also reduced in patients treated with 
Belimumab; however, as far as severe flares are concerned, Belimumab 10 mg 
was superior over Belimumab 1 mg and standard of care. At the same time Beli-
mumab had a steroid sparing effect; in fact the proportion of patients with at least 
50% reduction in prednisone dose were significantly greater with belimumab 
10 mg at every visit from visit 24 to 52, again with a dose dependent response. 
However, the magnitude of the results of the two BLISS studies at 52 weeks and 
on the lack of effect of Belimumab at 76 weeks in BLISS 76 has been questioned. 
In this regard, it has to be mentioned that prednisone tapering during Belimumab 
treatment may restore residual disease activity. Hence a delicate balance is or-
chestrated between lowered steroid dosage and dampening of disease activity.
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Pregnancy and biological therapy: the role of GC combination
 
Monika Ostensen
National Center of Pregnancy and Rheumatic Disease, University of Trondheim, 
Norway
Biological drugs are used for an ever increasing proportion of rheumatic patients. 
Most biological agents are monoclonal antibodies of the IgG1 class. IgG is ac-
tively transferred through the placenta by Fc receptors on the trophoblast. Fetal 
exposure to IgG is very low during organogenesis, but placental transfer starts at 
the beginning of the 2nd trimester and increases until term when maternal and fe-
tal serum levels are equal or higher in cord serum. Biological agents that contain 
an Fc-part are also transferred actively through the placenta. 
Among the TNF inhibitors infliximab, adalimumab, and golimumab show in-
creasing transplacental passage throughout pregnancy. Transplacental passage of 
etanercept, a fusion protein directed against the TNF receptor, is much less than 
for the complete antibodies, and is minimal for the pegylated Fab fragment cer-
tolizumab which lacks the Fc part of immunoglobulin. Published experience for 
infliximab, adalimumab, etanercept and certolizumab have not shown an increase 
in miscarriage or congenital malformations. No human data on golimumab dur-
ing pregnancy have been published. It appears that TNF inhibitors are not terato-
gen and may be used pre-conceptional and in the first trimester, in the 2nd and 3rd 
trimester only when severity of maternal disease requires it. 
The B cell inhibitor rituximab appears not to be a strong human teratogen. 
However, 2nd and 3rd trimester exposure causes B cell depletion in the fetus 
with unknown long-term effects in the child. Abatacept and tocilizumab should 
be discontinued three months before conception because experience in human 
pregnancy is up to date very limited. Because of its short half-life, prophylactic 
discontinuation of anakinra before a planned pregnancy is not necessary, but it 
should not be continued during pregnancy.
Combination of biological drugs with corticosteroids (Cs) may occur in women 
planning a pregnancy since methotrexate has to be discontinued before pregnan-
cy. Doses of corticosteroids >7.5 mg increase the risk of side effects in pregnant 
patients. Exposure of the fetus to high doses of Cs in the 2nd and 3rd trimester 
increases the risk for intrauterine growth restriction and premature delivery. A 
combination of TNF inhibitors and Cs can suppress the immune function of the 
child though this has not been studied in detail.
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Glucocorticoids and chronotherapy in RA
*Maurizio Cutolo, *Alberto Sulli, **Rainer H Straub
*Research Laboratory and Academic Unit of Clinical Rheumatology, Depart-
ment of Internal Medicine, Universuty of Genova - Italy
**Laboratory of Experimental Rheumatology & Neuroendocrine Immunology, 
Department of Internal Medicine I, University Hospital of Regensburg, Regens-
burg, Germany
Glucocorticoids are usually given after the patient affected by arthritis (i.e. rheu-
matoid arthritis (RA)) awakes in the morning. At a time clinical symptoms such 
as gelling and stiffness are already at a maximum, but this is not the optimal mo-
ment during the day. The question arises why night-time glucocorticoids can be 
more beneficial than morning glucocorticoids.
In fact, recent data of a double blind placebo-controlled randomized study in 
hundreds of patients with RA demonstrated a more marked and significant effect 
on morning stiffness and serum IL-6 when glucocorticoids are given at 2 am 
in the night (1). Again the question appears why immunosuppressive treatment 
with glucocorticoids can inhibit proinflammatory sequelae better when given at 
an early time point at 2 am (2). These observations are very important in un-
derstanding antiinflammatory counter-regulation of immune responses. It is has 
been demonstrated that glucocorticoids induce the transcription of the inhibi-
tor of kappa B (IκBα) gene, which results in an increased rate of IkBα protein 
synthesis and inhibition of proinflammatory NF-κB effects. Other studies have 
shown that glucocorticoids can interfere with the transcriptional activation po-
tential of DNA-bound NF-κB complexes leading to antiinflammatory effects (3). 
These effects appear very early in the turning on phase of a proinflammatory re-
sponse (early stimulation of immune cells). The turning-on phase of a proinflam-
matory reaction is much more vulnerable to immunosuppressants as compared 
to the turning-off phase. Therefore, the regulation of an important proinflam-
matory factor such as TNF increase, must occur very early because otherwise 
an overwhelming secretion of this harmful cytokine would occur. In view of 
the circadian rhythms and the impact of the timing of immunosuppressive ad-
ministration on efficacy, there is great interest to explore timed-release forms of 
cytokine neutralizers (on the basis of small molecules) or cronobiological admin-
istration of antiproliferative drugs such as methotrexate as therapeutic modality 
in RA (1). Reformulating old drugs such as glucocorticoids (nocturnal hormone) 
in new circadian drug delivery forms has recently optimized the clinical efficacy 
and improved immunosuppressant activities in RA (4). In a 12-week, multicen-
tre, randomized, double-blind trial, 288 patients with active RA were randomly 
assigned to either a modified-release prednisone tablet (releasing prednisone at 
2am) or to an immediate-release prednisone tablet. The modified-release tablet 
was taken at bedtime (10pm) and prednisone was released with a delay of 4 h 
after ingestion. This treatment was compared with morning administration of 
immediate-release prednisone as an active comparator showing a significant su-
periority (4). In addition, no worsening of adrenal impairment was observed on 
treatment with nighttime-release prednisone in patients with low responsiveness 
to CRH testing before the treatment with modified-release prednisone, and no 
change of adrenocortical function was observed over 12 months (5). In conclu-
sion, since immunosuppressive effects of glucocorticoids are fast, it becomes 
understandable why night-time availability of glucocorticoids has a stronger im-
munosuppressive effect compared to treatment in the morning.
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Systemic metabolic signaling in acute and chronic gastrointestinal 
inflammation of inflammatory bowel diseases
Thomas Karrasch, Florian Obermeier and Rainer H. Straub
Department of Internal Medicine I, University of Regensburg, Regensburg, Germany
Background. Acute and chronic intestinal inflammation stimulates innate and 
adaptive immune systems, thereby increasing energy demand of activated im-
mune cells. Energy regulation by systemically released mediators is of critical 
importance for homeostasis. We asked how systemic metabolic mediators are 
affected during intestinal inflammation. 
Methods. A total of 123 patients suffering from Crohn’s disease (CD), 76 pa-
tients with ulcerative colitis (UC), and 21 healthy controls were recruited. Pa-
tients receiving systemic steroids or therapy regimens including biologicals 
(anti-TNF) were excluded from the study. Serum levels of IL-6, CRP, insulin, 
glucose, free fatty acid, and RBP-4 were measured by ELISA and RIA. 
Results. Intestinal inflammation was accompanied by elevated systemic inflam-
matory parameters such as IL-6 and CRP in UC and CD and, concomitantly, with 
elevated insulin levels and increased insulin/glucose ratio in patients with UC. This 
indicates insulin resistance in liver, muscle, and fat. In addition, intestinal inflam-
mation was associated with elevated levels of circulating free fatty acids in UC and 
CD, indicating an activation of the organism’s appeal for energy-rich substrates 
(energy appeal reaction). RBP-4 serum levels were also high in acute and chronic 
intestinal inflammation in UC and CD, which can support insulin resistance.
Conclusions. The organism’s “energy appeal reaction” in response to acute and 
chronic inflammation provides free energy in the circulation, which is needed by 
inflammatory cells. A major mechanism of the re-direction program is insulin 
resistance. New therapeutic strategies might be developed in the future, directly 
impacting on the storage and utilization of energy-rich fuels.
P02
No difference in DKK-1 protein content in synovial tissue, synovial 
fluid, and plasma samples of rheumatoid arthritis and osteoarthritis 
patients 
*Zsuzsa Jenei-Lanzl, *Torsten Lowin, *Christine Wolff, *Georg Pongratz, *Hubert 
Stangl, *Julia Kunath, *Susanne Klatt, **Silvia Capellino, *Rainer H. Straub 
*Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, 
Department of Internal Medicine, University Hospital Regensburg, Germany. 
**Department of Pediatrics, Division of Endocrinology, Johns Hopkins Univer-
sity School of Medicine, Baltimore, Maryland 21287, USA. 
Objective. In arthritic diseases, the dysbalance between Wnt mediated bone for-
mation and TNF/RANK ligand mediated bone resorption has been described. In 
rheumatoid arthritis (RA), the inflammatory situation with high TNF concentra-
tions increases the expression of the Wnt antagonist Dickkopf (DKK-1) leading 
to bone erosions. In contrast, active Wnt signaling promotes osteoblastogenesis 
and osteophyte formation in osteoarthritis (OA)*. It is also known that inflamma-
tory processes in experimental arthritis are strongly affected by the sympathetic 
nervous system (SNS): In the early acute phase of experimental arthritis the SNS 
acts proinflammatory, whereas in the late chronic phase the SNS is anti-inflam-
matory. It was the aim of this study to analyze DKK-1 content in human OA and 
RA synovial tissue samples with or without sympathetic influence. 
Methods. Synovial tissue, synovial fluid, and blood plasma samples were ob-
tained from patients with rheumatoid arthritis (RA, n=10) and osteoarthritis (OA, 
n=10). Synovial fluid and blood plasma DKK-1 concentration was determined 
immediately after taking of samples using ELISA technique. Release of DKK-1 
from synovial tissue was determined by tissue superfusion with or without no-
radrenergic stimulation (noradrenaline 10-9 to 10-5 M) for 6 hours. 
Results. DKK-1 concentration in OA synovial tissue superfusates without no-
radrenergic stimulation was significantly higher compared to RA. There were 
no differences in DKK-1 levels between RA and OA in synovial fluid and blood 
plasma samples. In OA superfusates treated with 10-5 M noradrenaline, DKK-1 
concentration was significantly increased which was not observed in RA. Con-
clusion. In summary, this study presents that DKK-1 release from synovial tissue 
is higher in OA compared to RA. In addition, a sympathetic influence via no-
radrenaline at high concentrations might increase DKK-1 release in OA synovial 
tissue. These unexpected findings might depend on relatively low inflammatory 
levels in our RA patients with longstanding chronic inflammation or concomitant 
immunosuppressive medication. 
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Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with 
psoriatic arthritis: results of a phase 3, randomized, controlled trial 
Arthur Kavanaugh1, Philip J. Mease2, Juan J. Gomez-Reino3, Adebajo Adewale4, 
Jürgen Wollenhaupt5, ChiaChi Hu6, Randall Stevens6, Maurizio Cutolo7
1University of California San Diego, San Diego, CA
2Swedish Medical Center and University of Washington School of Medicine, 
Seattle, WA
3Hospital Clinico Universitario, Santiago, Spain
4University of Sheffield, Sheffield, UK
5Schön Klinik Hamburg Eilbek, Hamburg, Germany
6Celgene Corporation, Warren, NJ
7Clinical Rheumatology University Medical School of Genova, Italy
Purpose. Apremilast, an oral phosphodiesterase 4 inhibitor, works intracellularly 
to modulate a network of pro- and anti-inflammatory mediators, including those 
implicated in the etiopathogenesis of psoriatic arthritis (PsA). This phase 3 study 
(PALACE 1) compared the efficacy and safety of apremilast with placebo (PBO) 
in subjects with active PsA despite previous DMARDs and biologics.
Materials and Methods. Subjects were randomized 1:1:1 to PBO, apremilast 20 
mg BID, or apremilast 30 mg BID stratified by baseline DMARD use. At wk 16, 
subjects with <20% reduction from baseline in swollen and tender joint counts 
were re-randomized to apremilast 20 mg BID or 30 mg BID (PBO group), or 
remained on their initial dose (apremilast groups). All subjects then continued 
assigned treatment through wk 24. Stable concurrent treatment with MTX, sul-
fasalazine, leflunomide or a combination was allowed. 
Results. 504 subjects were randomized and comparable across treatment groups 
for demographics, disease characteristics, and prior/concurrent therapy. Of note, 
23.6% of patients had prior biologic exposure, including 9.3% considered bio-
logic failures. At baseline, 64.9% were taking DMARDs (54.2%, MTX). At wk 
16, a significantly greater proportion of subjects treated with apremilast 20 mg 
BID (31.3%; p=0.0140) and 30 mg BID (41.0%; p<0.0001) achieved an ACR20 
vs PBO (19.4%) (Table). In subjects receiving apremilast 30 mg BID, higher 
ACR20 responses were seen in subjects receiving apremilast monotherapy and 
in biologic-naïve subjects compared with the overall population response. At wk 
24, apremilast was associated with significant differences vs PBO in ACR20, 
ACR50, ACR70, HAQ-DI, SF-36 Physical Function scores, DAS-28, and EU-
LAR response. In general, response rates were higher with apremilast 30 mg 
BID. Apremilast was generally well tolerated. Adverse events (AEs) occurring in 
≥5% of any treatment group were diarrhea (PBO, 2.4%; apremilast 20 mg BID, 
11.3%; and apremilast 30 mg BID, 19.0%), nausea (6.5%, 9.5%, and 18.5%), 
headache (4.8%, 10.1%, and 10.7%), and upper respiratory tract infection (3.6%, 
6.0%, and 4.2%). The majority (>95%) of AEs were mild or moderate; discon-
tinuations due to AEs were similar across all treatment arms (5-7%). Serious 
AEs occurred in 7 (PBO), 8 (apremilast 20 mg BID), and 9 (apremilast 30 mg 
BID) subjects. No opportunistic infections (including TB) or lymphoma were 
observed, and there was not a greater risk of cardiovascular events.
Conclusion. Apremilast significantly improved signs and symptoms of PsA and 
resulted in statistically and clinically meaningful improvements in physical func-
tion. Apremilast was generally well tolerated and no new safety or laboratory 
signals were detected. 
P04
Lower serum dehydroepiandrosterone and androstenedione levels 
in pre-rheumatoid arthritis versus normal control women: correla-
tions with lower serum cortisol levels
*Kevin B. Elmore, *Azeem A. Rehman, *Ned J. Goertzen, **Robert T. Chat-
terton, *Jean C. Aldag, *Alfonse T. Masi
*University of Illinois College of Medicine (UICOMP), Peoria, IL 61656, USA
**Northwestern University (NWU), Chicago, IL 60611 USA
Background. Rheumatoid arthritis (RA) is a leading cause of disability, occur-
ring two or three times more frequently in women than men, and increasing in 
incidence during adult aging. Low serum adrenal androgens, including andros-
tenedione (Δ4A), dehydroepiandrosterone (DHEA), and its sulfate (DHEAS), 
have previously been reported in female RA patients. As yet, no study has been 
performed on androstenedione and DHEA levels before onset of RA (pre-RA).
Objective. This study investigates a broad panel of adrenal steroids, including 
glucocorticoids and androgens, and their enzymatic pathways, to determine if dif-
ferences occur between women who later develop RA versus matched controls.
Study Method. “Operation CLUE” is a nested case-control cohort study which 
enrolled 12,381 females of Washington Co., Maryland, in 1974.  The pre-RA cas-
es had later onset of American College of Rheumatology (ACR) criteria-positive 
RA (from 1977–1992). Four controls (CN) were matched to each pre-RA case 
on gender, race, and cohort entry age. A comprehensive panel of adrenocortical 
steroids was assayed on the baseline 1974 stored sera.  Levels were standardized 
by menopausal status and compared in 36 female pre-RA vs 144 CN, by t-tests 
and age-adjusted partial correlations.
Results. Mean androstenedione levels were lower in total pre-RA vs CN subjects 
(p=0.015). When analyses were restricted to women with cortisol levels less than 
the population mean, the preceding Δ4A difference was magnified in these sub-
jects (p=0.005). Also, in subjects having lower cortisol, the mean DHEA level 
was lower in pre-RA vs CN women (p=0.012). The enzyme leading to Δ4A 
production, 17,20 lyase, also tended (p=0.053) to be lower in pre-RA than CN 
among those subjects having lower mean cortisol values. The pre-RA women 
who had lower Δ4A levels tended (p=0.097) to develop clinical RA sooner after 
entry into the cohort than the remaining of pre-RA cases.
Conclusions. Study data indicate that women who later developed clinical RA 
had combined lower baseline cortisol and adrenal androgens (AAs), DHEA and 
Δ4A, than matched cohort women. Physiologically, cortisol levels remain con-
stant during aging, but AAs progressively diminish. Adrenal function may also 
decline more rapidly with aging in a subset of pre-RA women having combined 
lower cortisol and AA levels, than occurs in a control population. Women with 
relative adrenal insufficiency may have lesser control of inflammatory pathways 
involved in the multifactorial development of RA.
P05
Combined interactions between dexamethasone and CTLA4-Ig 
(Abatacept) on activated cultured human macrophages
*Cutolo M, *Montagna P, *Soldano S, **Contini P, ***Villaggio B, *Sulli A, 
*Seriolo B, *Brizzolara R
*Research Laboratory and Academic Unit of Clinical Rheumatology, DIMI, Uni-
versity of Genova, Genova, Italy
**Laboratory of Clinical Immunology, DIMI, University of Genova, Genova, 
Italy
***Laboratory of Nephrology, DIMI, University of Genova, Genova, Italy 
Background. In clinical practice, the combination of glucocorticoids and CT-
LA4-Ig allows to obtain larger clinical improvement in rheumatoid arthritis (RA) 
patients compared to CTLA4-Ig monotherapy. In vitro studies showed that CT-
LA4-Ig binds to CD86 on human macrophages and that, besides its effect on T 
cells, induces reverse signaling on macrophages upon the binding [1-3]. 
Aim. The aim was to investigate the anti-inflammarory effects of dexamethasone 
(DEX) alone or combined with CTLA4-Ig on cultured human macrophages. 
Methods. THP-1 cells, activated into macrophages (PMA 0.05 μg/ml; 24 hrs), 
were cultured for 48 hrs with DEX (10-7 M) alone, or combined with CTLA4-
Ig (500 μg/ml). Cells untreated and treated with CTLA4-Ig alone, were used as 
controls. CD86 expression was evaluated by immunofluorescence (IF) and by 
flowcytometry (FACS). In addition, qRTPCR for IL-1β, TNF-α and IL-6 gene 
expression was performed at 1, 3 hrs after treatments. 
Results. Qualitative IF of CD86 demonstrated a decrease of the untreated mac-
rophages positivity after DEX treatment alone and, more prominently after DEX 
plus CTLA4-Ig-combined treatment. Quantitative FACS revealed 25.4% of 
CD86 positivity in untreated cells. The CD86 expression on cells treated with 
DEX alone was reduced, as well as in CTLA4-Ig-treated cells, by 78% and 57%, 
respectively, compared to untreated cells. DEX plus CTLA4-Ig induced an evi-
dent CD86 decrease by 97%. qRTPCR showed in macrophages treated with DEX 
Table. Primary and select secondary end points
 
 PBO (n=165) Apremilast Apremilast 
  20 mg BID 30 mg BID
  (n=163) (n=161)
ACR20 at wk 16, % 19.4 31.3* 41.0†
APR alone (n=172) 10.5 31.5* 50.8†
APR+DMARDs (n=317) 24.1 31.2‡ 35.0‡
ACR20 at wk 16 23.7 31.2‡ 43.3*
Biologic-naïve subjects (n=363) 
APR alone (n=89) 11.5 24.1‡ 58.8*
APR+DMARDs (n=274) 27.2 33.3‡ 37.2‡
Select secondary end points 
   at wk 24   
ACR50, % 4.2 15.3* 19.9†
ACR70, % 0.6 5.5* 11.2†
HAQ-DI, LS mean change from -0.077 (0.037) -0.212 (0.037)* -0.260 (0.037)* 
   baseline (SE) 
DAS-28, LS mean improvement 0.20 (0.087) 0.66 (0.087)* 0.91 (0.087) † 
   from baseline (SE) 
Good or moderate EULAR 29.1 45.4* 51.6† 
   response achievement, % 
SF-36 Physical Function, LS 1.46 (0.671) 3.50 (0.675)* 5.06 (0.674)† 
   mean change from baseline (SE) 
 
Efficacy analyses were conducted using the per-protocol population (N=489); last observa-
tion carried forward was used for missing data.
*p<0.05; †p≤0.0001;‡p=non-significant vs. PBO.
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alone or plus CTLA4-Ig-combined treatment, after 1 hr, a reduction for the ex-
pression of all assayed cytokines. CTLA4-Ig alone reduced IL-1β, TNF-α and 
IL-6 expression at 3 hrs, but not at 1 hr from treatment. At 3 hrs from DEX and 
DEX plus CTLA4-Ig treatment, cells still showed a reduction of IL-1β and IL-6 
gene expression. 
Conclusions. Both DEX and DEX plus CTLA4-Ig treatments, induce a reduc-
tion in CD86 expression and an anti-inflammatory effect on human macrophages, 
by decreasing cytokine gene expression. The results of the combined treatments, 
seems mainly due to the CTLA4-Ig/CD86 binding and partially related to the 
genomic effects of DEX and might explain the improved clinical conditions in 
RA patients treated with CTLA4-Ig and glucocorticoids (1,4). 
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P06
A favorable response with rituximab therapy in a lupus patient 
with digital gangrene 
Nursen Düzgün,Önay Keçik,Orhan Küçüksahin 
Ankara University Faculty of Medicine, Department of Internal Medicine- Rheu-
matology, Ankara, Turkey
We report a 38-year-old female patient who had digital ischemic lesions of hands 
and systemic lupus erythematosus (SLE) including arthritis (Jaccoud arthritis), 
photosensitivity, oral ulcers, renal disease, and positive ANA, RNP antibody and 
anti-beta 2 glycoprotein 1-IgA isotype. She had high disease activity of lupus. 
There was no history of obstetric morbidity and other vascular events.
Laboratory findings: white blood cell: 5.6 x109/L, Hb:11.9 g/dL, platelet :276 
x109/L, Hct:35.4 %, eritrosit sedimentation rate:120 mm/h, C-reactive protein: 
80mg/L,  eser proteinuria and microscopic hematuria on urinalysis. Kreatinin and 
hepatic enzymes were within normal values.
Autoimmune serology showed ANA (1/3200 titer, ++++, speckled pattern), 
U1RNP (+++), p-ANCA (+), anti-beta2 GP1-IgA isotype (43,5 U/mL; normal: 
<5 U/mL). There was hypocomplementemia (C3:0,647 g/L, C4 0,0758 g/L; nor-
mal : 0.9-2g/L and 0.1-0.4 g/L, respectively) ds-DNA and Sm antibodies and 
rheumatoid factor were negative. Microbial analyses were negative. Electrocar-
diographic, echocardiographic and Computer Tomography (CT) of the thorax 
were unremarkable.  
Initial treatment was started with glucocorticoid (1mg/kg/day), aspirin (300 mg/
day), intravenous prostaglandin (2 mcg/kg/min) and intravenous cyclophospha-
mide (500 mg/m2). Digital ischemia showed a serious progression to the digital 
gangrene over one month in spite of follow up under treatment with glucocorti-
coid, immunosuppressant, antiaggregant and potent vasodilatator agents. Rituxi-
mab (RTX) with 2 infusions of 1g at 14-day intervals was added to the treatment 
regimen. After 6 months, second cycle of RTX therapy was given. During the 
following, a complete recovery of digital lesions and the regression of active 
disease signs were observed, and acute phase responses receded. The patient is 
still clinical remission with glucocorticoid (10mg/day), aspirin (100mg/day), 
azathioprine (2.5mg/kg/day) and hydroxychloroquine (200mg/day) for the last 2 
years. As a conclusion in patients with progressive digital ischemic lesions and 
systemic lupus erythematosus under traditional immunosuppressive agents, RTX 
can be an option. 
P07
17β-estradiol and 5α-dihydrotestosterone influence integrin ex-
pression levels and influence IL-6 production in an integrin β1-
dependent manner in synovial fibroblasts from RA and OA donors
*Katharina Weiß, **Rainer H. Straub and **Torsten Lowin
*Clinic und Polyclinic of Dermatology, University Hospital of Regensburg, 
D-93053 Regensburg, Germany.
**Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, 
University Hospital of Regensburg, D-93053 Regensburg, Germany.
Background. In rheumatoid arthritis (RA), synovial fibroblasts (SF) secrete large 
amounts of IL-6, IL-8 and matrix metalloproteinases (MMPs) which are crucial 
for cartilage destruction. The production of pro-inflammatory factors is in part 
mediated by enhanced constitutive integrin signaling since expression of these ad-
hesion molecules is increased in RA. Furthermore, anti-inflammatory androgens 
are reduced in RA while pro-inflammatory estrogen metabolites are increased. 
Since sex hormones modulate integrin levels and function in a variety of cell 
types, this study demonstrates the influence of sex hormones on integrin expres-
sion and cytokine production under basal and inflammatory conditions in SFs.
Methods. Integrin levels were determined by flow cytometry. Cytokines were 
detected by sandwich ELISA.
Results. 5α-dihydrotestosterone (DHT) and 17β-estradiol (E2) marginally in-
fluenced levels of integrin subunits α1, α3, α5 and αν and dose-dependently 
decreased integrin β1 levels. A decrease in β1 integrin by DHT correlated with 
decreased IL-6 production in RA while decreased β1 by estrogen correlated with 
reduced IL-6 levels in OA. Furthermore, DHT and E2 decreased IL-1β stimulated 
IL-6 and IL-8 production only when SFs were pre-incubated with respective sex 
hormones. The effects of DHT and E2 were enhanced under COX-2 inhibition.
Conclusion. DHT and E2 elicit ant-inflammatory effects by downregulating IL-6 
production in SFs. This occurs partly via an integrin β1 dependent pathway under 
basal conditions. Under pro-inflammatory conditions, E2 and DHT might act via 
a COX-2 metabolite since a) pre-incubation with DHT and E2 is necessary to 
elicit anti-inflammatory effects and b) effects are enhanced by COX-2 inhibitor 
nimesulide.
P08
The synthetic cannabinoid and CB1/CB2 agonist WIN55212,2 de-
creases the production of inflammatory mediators in rheumatoid 
arthritis synovial fibroblasts by activating TRPV1 and non-cannab-
inoid receptor targets
Torsten Lowin, Angelika Gräber and Rainer H. Straub
Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, 
University Hospital of Regensburg, D-93053 Regensburg, Germany.
Background. In rheumatoid arthritis (RA), synovial fibroblasts (SF) secrete 
large amounts of IL-6, IL-8 and matrix metalloproteinases (MMPs) which are 
crucial for cartilage destruction. RASFs are sensitive to the action of cannabi-
noids and they express cannabinoid receptors type I and II (CB1 and CB2) and 
the transient receptor potential channels type vanilloid (TRPV1) and ankyrin 
(TRPA1). The synthetic cannabinoid WIN55212,2 demonstrated strong anti-in-
flammatory effects in monocytes and synovial fibroblasts only in high concentra-
tions in a non-cannabinoid receptor dependent manner. In this study we assessed 
the ability of WIN55212,2 to modulate cytokine and MMP-3 production over a 
wide concentration range under normoxic and hypoxic conditions in synovial 
fibroblasts from RA and OA donors. 
Methods. MMP-3, IL-6 and IL-8 were determined by ELISA. 
Results.  Under normoxic conditions and IL-1β as inducer of cytokine produc-
tion, WIN55212,2 did not significantly modulate IL-6 and IL-8 production in 
concentrations below 2μM, while higher concentrations completely inhibited 
cytokine production. This was not dependent on activation of either CB1 or CB2. 
Under hypoxic (1% O2) conditions and TNF as inducer of cytokine production, 
WIN55212,2 (10-6M to 10-12M) dose-dependently inhibited IL-6, IL-8 and MMP-
3 production. In RASFs but not OASFs, the effects of WIN were attenuated by 
capsazepine, a TRPV1 antagonist. Furthermore, fetal calf serum content in cul-
ture media strongly influenced the efficacy of WIN55212,2.
Conclusion. The synthetic cannabinoid WIN55212,2 exhibits anti-inflammatory 
effects in synovial fibroblasts independent of CB1 and CB2. Our results indicate 
a TRPV1 dependent mechanism that might be coupled to cellular energy status 
since decreasing serum content and hypoxia augment the effects of WIN55212,2 
on production of IL-6, IL-8 and MMP-3.
P09
The endocannabinoid-like fatty acid amides palmitoylethanola-
mine and oleoylethanolamine exert anti-inflammatory effects in 
syn ovial fibroblasts from RA and OA donors
Torsten Lowin, Angelika Gräber and Rainer H. Straub
Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, 
University Hospital of Regensburg, D-93053 Regensburg, Germany.
Background. In rheumatoid arthritis (RA), synovial fibroblasts (SF) secrete large 
amounts of IL-6, IL-8 and matrix metalloproteinases (MMPs) which are crucial 
for cartilage destruction. While the endocannabinoids anandamide (AEA) and 
2-arachidonylglycerol (2-AG) are abundant in RA and OA synovial tissue and 
fluid, the related fatty acid amides palmitoylethanolamine (PEA) and oleoyletha-
nolamine (OEA) are only found in synovial tissue from healthy individuals. Al-
though AEA and 2-AG are considered to be anti-inflammatory, OEA and PEA are 
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important for the resolution of inflammation. Therefore, in this study we assessed 
the ability of PEA and OEA to modulate cytokine and MMP-3 production under 
normoxic and hypoxic conditions in synovial fibroblasts from RA and OA donors. 
Methods. MMP-3, IL-6 and IL-8 were determined by ELISA. 
Results. Under normoxic conditions and IL-1β as inducer of cytokine and MMP-
3 production, PEA and OEA significantly reduced IL-6 and IL-8 production in 
RASFs but only slightly in OASFs. Under hypoxic (1% O2) conditions and TNF 
as inducer of cytokine and MMP-3 production, OEA (10-5M to 10-11M) dose-
dependently inhibited IL-6, IL-8 and MMP-3 production only with concomitant 
COX-2 but not FAAH inhibition. In analogy to that, PEA decreased IL-6, IL-8 
and MMP-3 which was also enhanced by COX-2 inhibition.
Conclusion. The endocannabinoid-like compounds PEA and OEA exhibit anti-
inflammatory effects in synovial fibroblasts which was enhanced by COX-2 inhi-
bition. Since both compounds do not bind COX-2 directly, our results indicate an 
indirect mechanism possibly involving degradation of PEA and OEA by FAAH 
and subsequent oxygenation by COX-2. 
P10
Osteoclast progenitors, fibroblast-like cells and draining lymph 
node cells induce catecholaminergic-to-cholinergic transition of 
sympathetic nerve fibers under healthy conditions but not in highly 
inflamed arthritic tissue
*Stangl H., **Muschter D., **Graessel S., *Straub R.H. 
*Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, 
Department of Internal Medicine I, University Hospital Regensburg, Germany 
**Division of Experimental Orthopedic Surgery, Department of Orthopedic 
Surgery, University Hospital Regensburg
Sympathetic nerve fibers innervate bone and tissue adjacent to joints. They play 
an important role in bone and tissue homeostasis. Under certain conditions, sym-
pathetic nerve fibers can change their phenotype from catecholaminergic to cho-
linergic (see innervation of sweat gland and periosteum). This can be important 
because anti-inflammatory effects of acetylcholine have been described which is 
mainly mediated by the alpha7-nicotinic acetylcholine receptor. We asked wheth-
er this transition could also occur in the joint during collagen-induced arthritis 
(CIA) in mice or during rheumatoid arthritis (RA) and osteoarthritis (OA) in 
humans. Arthritic limbs from 30 immunized C57Bl/6J mice were collected at dis-
tinct time points covering all stages of the disease. Sections of mouse limbs and 
synovial tissue samples obtained from 30 OA and 12 RA patients were stained 
for tyrosine hydroxylase (TH, noradrenergic fibers), and for vesicular acetylcho-
line transporter (VAChT, cholinergic fibers). For co-culture experiments, sympa-
thetic ganglia were obtained from newborn mice and double-stained for TH and 
VAChT after a co-culture period of two to three days with osteoclast progenitors 
attained from the femoral and tibial bonemarrow as well as lymphocytes ob-
tained from the draining lymph nodes and fibroblast-like cells isolated from the 
paws of adult mice. In mouse joint area, an increase in the ratio of cholinergic 
to catecholaminergic nerve fibers appeared at day 35 after immunization. Most 
of the nerve fibers were located in joint-adjacent skin or muscle tissue, and only 
very few were detected in synovial tissue or near erosions. In human tissue sec-
tions, we were able to show cholinergic fibers in the synovial tissue of four OA 
patients but in none of the RA patients. Co-cultures of sympathetic ganglia and 
osteoclast progenitors as well as lymphocytes and fibroblast-like cells obtained 
from healthy mice showed more catecholaminergic-to-cholinergic transition 
when compared to experiments with the respective cells from arthritic mice. In 
men and mice, catecholaminergic-to-cholinergic transition is possible in less in-
flamed tissue of the joint but not in highly inflamed arthritic tissue.
P11
The spatial energy expenditure configuration and possible applica-
tions in an experimental model of arthritis 
Klatt Susanne
Experimental Rheumatology and Neuroendocrine Immunology, Internal Medi-
cine I, University Hospital Regensburg
Background. An autoimmune response with differentiation and proliferation 
of immune cells and the subsequent tissue-directed inflammatory process in the 
symptomatic phase of the disease are very energy-demanding. As recent calcula-
tions demonstrate, the activated immune system needs approximately 20% of the 
basal metabolic rate. During long standing inflammatory diseases like rheumatoid 
arthritis, a reallocation of energy-rich fuels to the activated immune system is 
necessary in order to nourish the inflammatory process. Energy consumption and, 
thus, ATP generation can be measured by studying the consumption of oxygen. 
The energy expenditure in different organs at different time points has never been 
investigated during immunization. We want to find out if, and how the energy ex-
penditure in different organs changes during the course of experimental arthritis. 
Methods and Results. A new technique termed “spatial energy expenditure 
configuration (SEEC)” was developed to demonstrate bodily areas of high en-
ergy demand. SEEC is based on removal of tissue during the course of arthritis, 
and subsequent determination of oxygen consumption. For that purpose, small 
weighed pieces of the respective organ with a size of 4 mm are placed in 24-well 
multidishes with integrated oxygen sensors, which allows for non-invasive de-
tection of oxygen consumption in vitro. SEEC was established in healthy control 
animals, arthritic animals and animals that underwent prior sympathectomy. We 
determined the oxygen consumption in spleen, thymus, draining lymph nodes, 
liver, kidney, brain and knee joints during the course of experimental arthritis 
for 70 days. In draining lymph nodes of arthritic DBA/1J mice we observed a 
marked increase in oxygen consumption during the course of arthritis (200%). 
Sympathectomy prior to immunization increases energy consumption in drain-
ing lymph nodes, which is most probably a sign of retention of leucocytes in 
the lymph node. C57BL/6 mice deficient for the important adipose triglyceride 
lipase revealed an increased oxygen consumption in the liver. This might be due 
to a lack of lipolysis activity, and therfore increased gluconeogenetic activity 
in the liver for the generation of energy rich fuels in form of glucose. ATGL-
deficient arthritic animals also showed higher energy demand in lymph nodes, 
adrenals and gut. 
Conclusions. The SEEC technique enables us to identify locations of high en-
ergy demand that are involved in the initiation and continuation of the autoim-
mune process in an animal model of arthritis. We identified the draining lymph 
nodes as target organ of the sympathetic nervous system, which will be further 
investigated. The technique will be applied to other chronic inflammatory disease 
models in order to detect further participating organs. 
P12
Limited correlations between sex hormones and nailfold micro-
angiopathy extent, peripheral blood perfusion and finger dermal 
thickness in a small cohort of systemic sclerosis patients
Ferrari G, Bernero E, Ravera F, Alessandri E, Ruaro B, Cutolo M, Sulli A
Research Laboratories and Academic Unit of Clinical Rheumatology, Depart-
ment of Internal Medicine, University of Genova, Genova, Italy. 
Background. 17beta-estradiol (E) has been shown to induce a significant in-
crease of fibronectin, collagen type I, and laminin synthesis in both normal and 
systemic sclerosis (SSc) fibroblasts in vitro (1, 2). Furthermore, dehydroepian-
drosterone sulphate (DHEAS) was found decreased in SSc patients in compari-
son with healthy subjects, whereas prolactin (PRL) was detected higher (3, 4). 
Aim. Clinical study to investigate possible correlations between sex hormone 
serum levels and nailfold microangiopathy extent, peripheral blood perfusion 
(PBP) and finger dermal thickness (FDT) in a small cohort of SSc patients. 
Methods. Twenty-three post-menopausal SSc patients (leRoy 2001 or ACR cri-
teria) were enrolled (mean±SD age 60±7, disease duration 8±5 years). Serum 
levels of E, total (Tt) and free testosterone (Tf), DHEAS, and PRL were evalu-
ated by standard methods. At the same time nailfold microangiopathy extent was 
assessed by videocapillaroscopy (NVC), in order to detect the pattern of micro-
vascular damage (“Early”, “Active”, “Late”) and the microangiopathy evolution 
score (MES) (5). In addition, PBP was quantified by both laser Doppler flowme-
try and laser speckle contrast analysis at the level of the fingertips (6). FDT was 
measured by high frequency ultrasound, as previously reported (7). 
Results. PRL was significantly higher in SSc patients with “Active” and “Late” 
pattern of microangiopathy in comparison with “Early” pattern (p=0.01). DHE-
AS, Tt and Tf were found progressively lower in patients with “Early”, “Active” 
and “Late” pattern of microangiopathy, but this was not statistically significant. 
A not statistically significant progressive increase of E was detected in patients 
with “Early”, “Active” and “Late” pattern of microangiopathy. Furthermore, no 
statistically significant correlation was found between investigated hormones and 
MES, PBP, and FDT. 
Conclusion. With the exclusion of PRL, which was found significantly higher 
in SSc patients with more advanced patterns of nailfold microangiopatrhy, the 
study demonstrates no significant correlations between sex hormones and nail-
fold microvascular damage extent, PBP and FDT. However, the small cohort of 
patients included into the study limited the possible significance of the analyzed 
parameters. 
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P13
NeuroEndocrine-Immunology in orthogeriatric patients: prelimi-
nary report on the acute modification of urinary cortisol and serum 
BDNF levels in Alzheimer’s disease after osteoporotic hip fracture
Martocchia A*, Curto M**, Comite F*, Scaccianoce S***, Xenos D***, Nasca 
C***, Girardi P**, Nicoletti F***, Falaschi P* and the Orthogeriatric Group*. 
*Unit of Geriatrics
**NESMOS Department
***Department of Human Physiology and Pharmacology, Sapienza University 
of Rome, Italy. 
The Orthogeriatric Group: De Marinis E, Stefanelli M, Toussan L, Devito A, 
Benvenuto R, Indiano I, Tafaro L, Rocchietti March M. 
Introduction. Osteoporotic hip fracture needs a specific clinical approach and 
treatment. When AD patients present an osteoporotic hip fracture, the clinical 
management becomes complex. Data are scanty about neuroendocrine-immune 
modifications in AD patients. Glucocorticoids on cerebral cells (e.g., neurons and 
astrocytes) are relevant for brain functioning (with resulting damaging effects 
in AD) and cortisol levels during the stress reaction (fracture and surgery) have 
important metabolic effects. Conversely, Brain Derived Neurotrophic Factor 
(BDNF) promotes neuronal maintenance, survival and synaptic plasticity (with 
resulting protective effects in AD). 
Objectives. The aim of the study was to investigate cortisol and BDNF levels in 
orthogeriatric patients with AD, with respect to controls. 
Methods. We enrolled: AD patients after surgery for hip fracture (n=5) (A), un-
treated AD patients (n=6) (B), healthy elderly (n=8) (C) and young (n=6) (D) con-
trols. AD diagnosis was carried out by NINCDS-ADRDA criteria; cognitive eval-
uation included Mini Mental State Examination. The serum BDNF levels were 
measured through ELISA (Promega). The urinary cortisol was collected from 8 
am to 8 pm (diurnal cortisol, Fd) and from 8 pm to 8 am (nocturnal cortisol, Fn). 
Results. After the stress condition (hip fracture with surgical intervention), AD 
patients showed a marked increase of Fd and Fn (457.5+174.0 and 203.8+144.3), 
when compared to untreated AD patients (120.5+26.2 and 74.5+70.7), elderly 
(115.3+40.7 and 64.4+47.1) and young controls (93.4+43.8 and 59.1+45.1 mcg) 
(Fd A vs. B p<0.01, A vs. C p<0.001, A vs. D p<0.001). The serum BDNF levels 
were reduced in AD patients after surgery for hip fracture (A, 8.4+2.4), with re-
spect to untreated AD patients (B, 9.6+2.4), elderly (C, 11.5+2.5) and young con-
trols (D, 16.1+2.1 pg/ml) (BDNF A vs. B n.s., A vs. C p<0.05, A vs. D p<0.001). 
≠ The osteoporotic hip fracture and the related surgery in AD induce a marked 
alteration of the neuroendocrine-immune parameters (BDNF and cortisol), syn-
ergistically involved in the clinical course of AD patients. Further studies are 
necessary in order to evaluate the effects of these modifications on cerebral 
(worsening of cognition and appearance of delirium) and general (alteration of 
glucose metabolism, risk of infection) functions.
P14
A prospective study in premenopausal women with Systemic Lupus 
Erythematosus supplemented with two different regimes of vitamin D: 
efficacy and safety at 12 months of follow-up
L. Andreoli1, F. Dall’Ara1,2, S. Piantoni1,2, N. Piva1, M. Cutolo3, A. Tincani1
1Rheumatology and Clinical Immunology, Spedali Civili and University of 
Brescia, Brescia 
2University of Pavia, Pavia, Italy 
3Research Laboratory and Division of Rheumatology, Department of Internal 
Medicine, University of Genova, Italy
Background. Systemic Lupus Erythematosus (SLE) patients (pts) are at risk for 
low vitamin D (VitD) levels because of lack of sun exposure. The current strategies 
of VitD supplementation do not seem to be sufficient not only for the prophylaxis 
of osteoporosis, but perhaps also to bring out the immunomodulatory effects of 
VitD that were highlighted by some in vitro studies. Few prospective studies are 
available on the effects of VitD supplementation SLE pts.
Objectives. To evaluate at 12 months of follow-up (T12) the efficacy, safety and 
the effects on SLE disease activity of an oral Cholecalcipherol supplementation 
given with 2 different regimens in a cohort of SLE pts.
Methods. 34 premenopausal SLE women were enrolled. A group of 18 pts (group 
S) were given “standard” regimen of supplementation (Cholecalcipherol 25.000UI 
once/month).The other 16 pts (group I) were given an “intensive” regimen (Chole-
calcipherol 300.000UI bolus, then 50.000UI once/month). The circulating levels of 
25-OH VitD were dosed every 3 months with a chemiluminescence assay kindly 
performed by the manufacturer (DiaSorin S.p.A., Italy).
Results. At baseline (T0) there was no significant difference in VitD levels in the 
2 groups. After 3, 6, 9 and 12 months “group I” showed significantly higher VitD 
levels (median at T12: 32.0 vs. 24.8 p=0,04). There were no significant differences 
upon season of enrollment. At T0 there was no difference in the proportion of suf-
ficient pts (>30 ng/ml) between groups (S:50%, I:56%), while at T12 sufficient 
pts were 28% in S and 75% in I (p=0.02). No significant variations in the levels of 
calcium, phosphorus and PTH were observed. No cases of PTH suppression. There 
were 3 cases of transitory mild hypercalciuria (2 in I, 1 in S). The pts had clinically 
quiescent disease (median SLEDAI 2 in S, 4 in I), but serologically active disease 
(positive anti-DNA and/or complement consumption in nearly 50% of the pts).  No 
statistically significant variation in the titers of anti ds-DNA and in the levels of C3, 
C4, CH50 was observed at T12 in both groups. 
Conclusions. Intensive supplementation with VitD has a safe profile as the stand-
ard regimen but it is able to induce sufficient levels in a larger number of pts. No 
particular effects on serological SLE parameters was noted, probably due to the 
stable remission state of the pts. More data will come from the second year of the 
study in which patients will switch to the other group of supplementation.
